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Abstract
There is a dire need for tools that can rapidly detect cancer treatment efficacy. A
cancer patient must endure the side effects of chemotherapy and radiotherapy. It will
be weeks before a change in the size of the tumor can be observed and the oncologist
has the information necessary to determine whether treatment is working. Valuable
time is lost searching for the right treatment and the right dose.
This thesis presents a sensor that can be implanted inside the body during a biopsy
procedure and wirelessly report on the tissue environment. The sensor has direct
access and can track metabolic markers, such as pH and oxygen, which have been
shown to predict outcome, dose, and response to cancer treatment. These markers
cannot be measured anywhere else except directly inside the tissue, and this sensor
provides that access. The probe allows for repeat, non-invasive measurement of the
same location after the initial biopsy.
The sensor consists of a small nuclear magnetic resonance (NMR) probe that has
a cavity filled with a contrast agent sensitive to the chemical of interest. An NMR
relaxation measurement of the contrast agent reveals the chemical concentration.
Wireless NMR measurements are performed with the aid of a reader probe that
resides outside of the body. The reader generates the excitation pulses and receives
the NMR signal. The sensor and reader have a mutual inductance that enables the
wireless measurement. The resonant coupling allows wireless NMR measurements
with enhanced signal-to-noise ratio. The field inside the sensor is amplified compared
to the surrounding tissue. The amplification localizes the measurement to the sensor
and eliminates any signal from the surrounding tissue. The coupled reader-sensor
performs standard NMR relaxation measurements. A method is presented to produce
the sensors in large numbers, and the sensors are tested in vivo.
The probe is designed to be implanted during a routine procedure and would be no
more invasive than existing clinical practice. The measurements can track tumor
progression and guide therapy before any physical changes can be observed, and the
patient can receive the right treatment as soon as possible.
Thesis Supervisor: Michael J. Cima
Title: David H. Koch Professor of Engineering
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Chapter 1
The clinical need
Sensors implanted inside the body offer the medical practitioner a unique vantage
point. They provide direct access to the physical and chemical environment of the
tissue that blood tests and imaging do not offer. Needle probes provide similar access
but are too invasive for routine and repeat use. This thesis presents a sensor designed
to be implanted during a biopsy procedure and to wirelessly report on its surround-
ings. The sensor performs repeat virtual biopsies on the same site using contrast
agents developed for magnetic resonance imaging (MRI) to measure proteins, oxy-
gen, and pH. This sensor is demonstrated primarily as a tool for monitoring cancer
but also finds applications in heart disease and traumatic injury.
1.1 Sensors inside the body
A sensor converts a physical or chemical property into information. Sensors that re-
side inside the body must provide medically useful information not available through
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other means, in a timely manner, and with minimal patient discomfort. These consti-
tute the sensor engineer's guiding principles. The usefulness of a sensor is measured
by how its availability changes clinical practice. Before building a sensor the engineer
should ask, "Will clinicians do anything differently based on this sensor's readings?"
This question is best answered in conversation with a practicing clinician.
The discussion with the clinician is also critical to determine where the sensor will
reside and how it will be deployed. All existing procedures in the standard of care
offer avenues for deploying a sensor. The chosen avenue will also constrain the
device's design. If key-hole surgery is performed with laparoscopic tools then the
device must be designed to fit through those tools. Designing for existing procedures
makes the deployment method obvious to a doctor or surgeon; it fits in neatly with
their current practice. The existing procedures also offer a method of payment since
reimbursement codes are already in the system. Avoiding additional procedures
reduces the risk to the patient and the overall cost of care.
How fast the sensor must measure depends on the application. An implantable
defibrillator must continuously monitor heart activity by taking measurements many
times per second. It does this to take necessary corrective action when abnormal
cardiac rhythms are detected. The information must be acted on immediately and
while the patient may be incapacitated. The direct monitoring enables the life-saving
instrument[1]. A sensor that tries to detect whether cancer therapy is working only
needs to measure once a day or less. Measuring every second will not add any
information, since no changes occur on that time-scale. The decision on how often to
sample influences how the device is powered and, consequently, how big the device
must be made. The defibrillator requires a large battery; whereas, the cancer sensor
presented here is powered wirelessly when the measurement is needed. It can be
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made smaller than commercially available medical batteries[2].
The PillCam is a small battery operated camera that exemplifies the importance
of patient comfort. It is swallowed and travels along the 9m tortuous path of the
digestive system taking photographs along the way[3, 41. It transmits the images
to a belt worn by the patient. The doctor receives a complete view of the GI tract
within one or two days. The imaging is done at home and avoids having to schedule
an endoscopy or colonoscopy. It has farther reach than either of those procedures
and is incomparably more comfortable. It is no surprise that it is finding uses for
diagnosing many types of gastrointestinal conditions.
There has been no discussion of science or engineering so far, because the most
important decision is what a sensor or device should do to provide the most benefit
to the patient. The technology is secondary; even the most technologically advanced
sensor is useless if it provides no meaningful information or if it will never be used.
The first decision is what the device should do, and then it is up to the engineer to
choose the best tool for the job.
The sensor presented in this thesis is designed to monitor cancer directly from within
a tumor. It measures clinically relevant markers that may indicate how the tumor is
progressing and whether therapy is proving effective. It takes weeks of treatment for
changes in the size of a tumor to manifest; changes in pH inside the tumor have been
detected as early as one day after treatment. The sensor response time, measured
in minutes and hours, is much faster than any anticipated change inside the tumor.
Designed to be implanted during a biopsy procedure, the sensor fits nicely into clinical
practice. It is no more invasive than the current standard of care, and the readout
is completely non-invasive.
29
1.2 Cancer
Worldwide, 7.5 million people died from cancer in 2008. That year approximately
12.7 million people were diagnosed with cancer. Cancers of the lung, breast and
colorectum made up one third of the total[5]. This year, in the United States alone,
over 1.6 million people will be diagnosed with cancer[6]. It can be expected that
the global diagnosis figure will rise dramatically as screening improves in developing
nations and more cases are detected.
Fortunately the number of cancer survivors is also increasing. Patient education and
better screening have lead to earlier detection and treatment[7]. There were over
13 million cancer survivors at the start of 2012; that number is expected to reach
19 million in the next decade[8]. Lesions are discovered through self-examination,
routine screening, and imaging. A cancer diagnosis, however, is almost exclusively
confirmed by a direct observation of the suspected tissue, that is, by biopsy[9]. A
needle biopsy is an invasive medical procedure that removes a small tissue sample
from inside the body. A pathologist microscopically examines the cells to look for
cancerous cells. The findings also help identify the type of cancer, which will point to
a particular course of therapy that is most likely to succeed. Treatment can involve
radiotherapy, chemotherapy, and/or surgery.
1.2.1 Treatment
Cancer treatment is shockingly ineffective. The underlying complexity of the disease
and the similarity between cancerous and normal cells make treatment challenging.
A single genetic mutation kickstarts a cycle of abnormal cell growth. These cells
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proliferate by evading the body's mechanisms for dealing with misbehaving cells.
They co-opt blood vessels to provide perfusion necessary for growth and eventually
escape from the tumor to invade the rest of the body[10, 11, 12]. The rapid rates of
cell division and genetic mutation make treatment very hard, and resistance develops
quickly even to treatments that were initially effective.
High rates of morbidity are associated with treating cancer. Many of the side effects
are not from the disease but from the treatment. Patients undergoing chemotherapy
or radiotherapy will likely experience fatigue, emotional distress, and severe pain[8].
Radiation therapy and surgery have fewer side effects because the treatment is lo-
calized, but tissue around the targeted area is still susceptible to damage.
Chemotherapy causes widespread damage to the body leaving no tissue unharmed;
every system is adversely affected. The list of side effects mirrors the list of tissues
and organs in the body. Chemotherapy reduces white blood counts, suppressing the
immune system and increasing the risk of secondary infections. The drugs damage
tissue throughout the digestive system, beginning in the mouth and gums, down the
throat, and along the lining of the intestines. The compromised digestive system
causes malnutrition and dehydration. Nausea and constipation are also common
side effects that compound these problems. The brain, skin, lungs, hair follicles,
and the peripheral nervous system are all adversely affected. Cardiotoxicity and
decreased bone density are major concerns. Add extreme fatigue and sleep disruption
to this, and it is not hard to see why over half of cancer patients experience severe
emotional distress[8]. These adverse effects are accepted because chemotherapy does
more damage to cancer cells than to healthy cells and because there are no other
options.
Early diagnosis and treatment are critical to long term survival. The right drug and
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dosage must be found early on to reduce the overall morbidity and prevent metastasis,
which is responsible for 80 % of all cancer related deaths[10]. Many drugs are effective
only for a small fraction of patients, and identifying the right drug for a patient is an
entire area of research[9]. It may be weeks after the treatment starts before doctors
can determine whether the drug is working or not. A sensor that directly monitors a
tumor could quickly and definitively assess response thus saving critical time in the
early stages of the disease.
1.2.2 New drug approvals
Recent drug approvals by the Food and Drug Administration (FDA) highlight the
dire need for methods to determine whether a drug is working or not. Four re-
cently approved drugs achieved less than 6 months increase in median survival with
overall response rates well below 50% of the treated population. The drugs only
modestly improve over previously approved drugs and some carry the potential for
serious toxicity in the heart and liver. Detecting treatment efficacy is extremely
important.
The human epidermal growth factor receptor 2 (HER2) is expressed in a third of
breast cancer patients and is predictive of poor reponse to therapy[13]. However,
the receptor can be targeted by antibodies and is the basis for several drugs. The
response rate to trastuzumab is 30% among HER2 positive patients compared with
just 9% across all patients. Added to chemotherapy it increased median survival
from 20 to 25 months[10]. Among the 2013 drug approvals is ado-trastuzumab
emtansine, which further extends the median survival to 31 months. The response
rate is slightly higher than trastuzumab but still under 50%[14, 15, 16]. Clearly
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there is an enormous benefit to identifying HER2 positive patients, but even among
this preselected population more than half of the patients will not respond. While
the newer drug may perform better across a patient population, there is no way of
knowing whether an individual patient will respond or not.
Regorafenib is a new drug for treating metastatic colorectal cancer[17]. It was ap-
proved despite only increasing survival by 1.4 months with a response rate of 5%.
The justification of approval in the summary review is telling, "While the absolute
magnitude of the treatment effects on survival [...] are small, the ability of any
single agent to demonstrate efficacy in this heavily pre-treated population represents
clinical benefit" [18].
This particular drug has relatively mild side effects, but that is not always the case.
Identifying the patients who are responding ensures that only those who are benefit-
ing are subjected to the side effects. A sensor could identify the 60% of HER2 positive
patients that aren't responding and reduce their risk of severe hepatic and cardiac
toxicity. If efficacy is detected quickly, then the 9% of HER2 negative patients who
might benefit from trastuzumab can be identified.
1.2.3 The tumor microenvironment
Cancer is more than just a collection of cells but behaves as an organ in which the sur-
rounding environment is as important as the constituent cells[19]. The extracellular
matrix, once thought to be a collection of cell-binding proteins, is increasingly being
recognized as an important contributor to the tumor lifecycle[10, 20]. It is actively
involved in cell proliferation, tumor growth, angiogenesis, and metastasis[21].
Even the physical arrangement of tumor cells is of critical importance; the future
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growth pattern of a tumor depends on the three dimensional arrangement of its
consituent cells[22]. A study on individual cells found that cells confined to a 20 pm
diameter post were likely to die but cells given a 50 pm plot continued to grow[23].
This raises the possibility of new treatments that target the tumor microenvironment
and not just the cells[24].
Cells removed from the body provide only part of the story. Cell morphology, gene
mutations, and surface protein expression tell only half the story. One can envision
that tumors will be characterized also by properties of tumor environment such as
oxygen, pH, and vascularization. Studying the tumor environment should be as
important as studying the response of cells in a culture dish. An oncologist with
feedback from a sensor inside the tumor could quickly try multiple drugs, identify
the one most likely to work, and start the patient on the right drug as soon as
possible. The disease will be treated sooner, and the patient will be spared the side
effects of ineffective treatment.
1.3 Thesis overview
This thesis presents an implantable NMR probe (figure 1-1) that can be implanted
directly inside a tumor using a standard biopsy needle. A variety of NMR contrast
agents are used to create sensors for oxygen, pH, and various proteins. The on-
board circuit enhances the signal strength, allows wireless remote measurement, and
eliminates any interfering signals from the surrounding tissue. The sensors exploit
nuclear magnetic resonance (NMR) for measurement. Chapter 2 provides a brief
introduction to NMR detection, resonant circuits, and mutual inductance. These
three topics form the basis of a wireless NMR probe. Chapter 3 presents the theoret-
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Figure 1-1: Biopsy implantable NMR sensor
ical framework and the design and construction of an implantable NMR probe. The
sensors rely on contrast agents to convert a chemical concentration or dose into an
NMR signal, and several examples are presented. Chapter 4 demonstrates on oxy-
gen sensor and tests it in a rat model. These measurements can predict the efficacy
of chemotherapy and radiotherapy. Chapter 5 presents a pH sensor for monitoring
the acidic environment of a tumor tested in a melanoma model in mice. Decreasing
pH following chemotherapy has been proposed as an indicator of treatment efficacy.
Chapter 6 shows how protein biomarkers can be measured as sentinels for myocardial
tissue damage caused by myocardial infarction or chemotherapy induced cardiotox-
ity. The prospects for human use are discussed in Chapter 7 along with additional
work needed to bring this to fruition.
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Chapter 2
Background
The sensor is comprised of a wireless nuclear magnetic resonance (NMR) probe that
contains a chemically sensitive contrast agent. NMR is not an obvious choice for a
miniaturized sensor because the signal is extremely weak compared to other tech-
niques. However, it offers an array of contrast mechanisms, and NMR can be per-
formed on opaque media and through tissue. Optical sensors require clean, trans-
parent samples. Optical detection through tissue is hindered by severe absorption
and scattering. Ionizing radiation (X-ray) or radioactive sources (positron emission
tomography) are unacceptable for repeat monitoring, while ultrasound lacks contrast
and chemical sensitivity. Overall NMR is an excellent modality for sensors inside the
body.
A wireless NMR probe is discussed in detail in Chapter 3. This chapter introduces
three important concepts that the sensors rely on: nuclear magnetic resonance, res-
onant circuits, and mutual inductance.
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2.1 Nuclear Magnetic Resonance
This thesis deals with a classical description of 'H NMR as introduced by Bloch[25].
This approach is acceptable because 1H is a spin-1/2 system, all samples are at high
temperature (300 K), and each sample contains approximately 1020 spins. The net
magnetization is not quantized, but rather a vector that can be manipulated with an
alternating magnetic field. Almost every NMR book includes the classical description
and derivation. A good overview is presented by Cowan[26]. Fukushima and Roeder
give substantial practical advice on building NMR probes[27]. Slichter's text covers
a graduate course on NMR[28], and the classic text by Abragam[29] is a complete
treatise on all aspects of NMR theory. Important papers by Hoult and Richards
present a clear method for determining the signal strength in an NMR experiment [30,
31] and a description of the NMR receiver[32]. The articles in the journal Concepts in
Magnetic Resonance[33, 34] are written from a pedagogical perspective, covering all
aspects of NMR. New research can be found in the Journal of Magnetic Resonance[35]
and Magnetic Resonance in Medicine[36].
2.1.1 Signal strength
NMR requires a magnetic field, BO = BOZ, created either with permanent magnets or
with superconducting coils in spectrometers and imaging systems (MRI). Convention
defines the direction of the field as 2 and refers to the 2-^ plane as the transverse
plane.
A small sample place inside a magnetic field will have a nuclear magnetization,
MO = MOZ, in the same direction as the magnetic field. This magnetization can be
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rotated by means of an oscillating magnetic field, B1 (t), that is perpendicular to the
static field, BO, and at a specific frequency called the Larmor frequency, wo = ^1Bo.
The constant of proportionality, 7, is the gyromagnetic ratio and depends on the
nucleus. Hydrogen, specifically 1H, has a gyromagnetic ratio of 2.675 x 108 s-1'T-1
or 42.57MHz T-1 . The nuclear magnetization of a small sample with spin number
I = in a magnetic field, BO, is given by,
MO= ' 2h2 NB (2.1)2 kB T
where the sample contains N protons at a temperature, T; h is the reduced Planck
constant; and kB is the Boltzman constant. Equation (2.1) gives clear guidance on
increasing the magnetization: increase the sample size, increase the field strength,
and lower the temperature. An implantable sensor goes against all of these. The
sensor must be small, the remote measurement limits the field strength, and the
temperature is fixed at 37 C. It is these constraints on the sample that require an
on board circuit.
An oscillating field applied perpendicularly to 2, such as,
B1 (t) = B1 sin(wot) , (2.2)
perturbs the nuclear magnetization, M, away from equilibrium. The transverse
component, Mx = M x 2, will precess around 2 at a frequency equal to the Larmor
frequency.
Much like music on an AM radio station, there is a slowly varying signal of interest
on a high frequency carrier. It is desirable to eliminate the high frequency term,
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sin(wot). A rotating reference frame is applied such that the oscillating field can be
described only by its time-varying magnitude and a phase term. The oscillating field
is turned on momentarily and rotates M at a rate, w, = ^yB 1, around the x axis.
The angle of rotation, #, is given by
# = wit = -yBit (2.3)
Two useful pulses are those that rotate the magnetization by 900 and 1800. The
first rotates the magnetization onto the transverse plane and satisfies the condition
'yBitgo = 7r/2. The second condition is simply twice the pulse area, -yBltiso = r, and
rotates the magnetization into the negative longitudinal direction, M = -MO.
The component of the magnetization in the transverse plane precesses around Z and
induces a voltage in a loop of wire around the sample. Faraday's law of induction
states that the voltage is proportional to the time rate of change of the magnetic
flux. Conveniently, the magnetic flux can be calculated by, MoiB1, where b 1 is the
magnetic field at the sample generated by unit current through the loop[31].The
induced voltage is
VNMR = wOMo5 1  (2.4)
where the frequency factor, wo, is due to the time derivative of the oscillating
magnetization [30]. This voltage will be measured by the coil, and the coil design
is also important. A wire loop carrying unit current has a magnetic field at the
center equal to
f51 = PO (2.5)2r
where r is the loop radius[38]. If the sample size is fixed, the coil should be as small
as the sample allows to maximize the induced voltage.
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The underlying assumptions are that the sample is uniform, the magnetic field is
constant, and the oscillating field is also of uniform magnitude. A spherical sample
in a long coil would certainly qualify. A small coil completely filled with sample will
have regions of lower field near the ends that cannot be ignored. The signal can be
calculated by first dividing the sample into many smaller samples. Each sample is
assumed to be uniform, and the contribution from each will be summed to give the
overall signal.
2.1.2 Relaxation
Various mechanisms are responsible for how the magnetization returns to equilib-
rium after it has been perturbed with the oscillating field[39, 40]. Two relaxation
time constants appear in Bloch's equations and are referred to as the spin-lattice
or longitudinal relaxation time, T1, and the spin-spin or transverse relaxation time,
T2 . When a sample is initially placed in a magnetic field, the nuclear magnetization
develops over time as follows:
A(t) = ZMO (1 - e/T1). (2.6)
A 900 pulse rotates the magnetization into the transverse plane, so M,, = MO and
Mz = 0. The transverse component decays towards zero and is given by
M y(t) = Mo exp-t/T2, (27)
while the longitudinal component returns to equilibrium following the previous equa-
tion.
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There is an assumption of a perfectly homogeneous magnetic field, but in reality this
is rarely the case. Slight variations in the magnetic field across the sample result
in a spatially varying Larmor frequency. If a 900 pulse is applied along X at time,
t = 0, the magnetization is rotated into the ^ direction. The precession continues
for a brief period of time, r. If the field variation across the sample is AB, then a
phase variation develops equal to
AO = yTAB. (2.8)
Hahn discovered that applying a 1800 pulse in this state could correct for this
deviation[41]. This 'refocusing pulse' effectively multiplies the phase by minus one.
The fastest precessing regions that had gained phase +# now have phase -0 and
vice versa for the slowest regions. The phase continues to accumulate, and at a time
t = 2r there will be no phase variation across the sample. This momentary construc-
tive interference is detected as an 'echo' by the receiver. Carr and Purcell extended
this work to allow for a train of pulses and echoes to measure relaxation time[42].
Meiboom and Gill modified this to eliminate compounding errors due to imperfec-
tions in the oscillating field[43]. The CPMG sequence is used almost exclusively in
systems with inhomogeneous fields and is shown schematically in figure 2-1. If the
initial 900 pulse is along X then the 180' pulses are alternately applied along +9 and
-Y. This ensures that any imperfections in the oscillating field do not accumulate
from one echo to the next. The peak of each echo is stored, and the decaying envelope
gives the material's inherent relaxation rate. Appendix A discusses an acquisition
modification used to increase the signal-to-noise ratio by using a least-squares esti-
mate on the entire acquired echo.
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Figure 2-1: Transverse relaxation is measured using the CPMG pulse sequence. A
900 pulse rotates the magnetization into the x - y plane. A train of refocusing pulses
compensates for field inhomogeneities and the signal appears as brief "echoes". The
envelope of the echo amplitudes (dashed) decays with a time constant, T2 .
Measuring longitudinal relaxation requires a different set of pulse sequences. The
nuclear magnetization is orders of magnitude smaller than the applied field and so
it is preferable to rotate the magnetization into the transverse plane for detection.
Saturation recovery is the preferred method for measuring T on systems with a
grossly inhomogeneous magnetic field, such as the NMR-MOUSE[44, 45]. The se-
quence starts with a series of pulses that saturate the magnetization such that the net
magnetization equals zero. The magnetization is allowed to recover for a time, T, at
which point a spin-echo method is applied to measure M,(T). The sequence, shown
in figure 2-2, is repeated for several different recovery times, and the full relaxation
profile is acquired. Multiple echoes can be acquire, instead of just one, using the
CPMG pulse sequence. This improves the estimate of M(T)[46].
Contaminants in a sample that perturb the field in their immediate vicinity can
increase the relaxation rate. These contaminants could be regions of different per-
meability such as magnetic particles, bubbles, or paramagnetic species such as oxy-
gen or gadolinium. The relaxation rates are often proportional to concentration.
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Figure 2-2: Saturation Recovery measures the longitudinal, or spin-lattice relaxation.
A burst of pulses with decreasing intervals completely saturate the magnetization
such that the net is zero. The system is allowed to recover for a time tau during
which the z-directed magnetization approaches the equilibrium magnetization, MO.
The relaxation is interrupted with a spin-echo sequence to generate an echo with
M(r) = Mo(1 - e-/T1). The relaxation time, T 1, is measured by repeating the
sequence for different recovery times.
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The relaxation-concentration curves can be used as sensors. Magnetic nanoparticles
tagged with antibodies form the basis of the contrast agents used in Chapter 6 for
measuring soluble protein biomarkers. Chapter 4 deals with an oxygen sensor that
exploits relaxation induced by paramagnetic oxygen in solution. Chemical exchange
is a process by which hydrogen atoms on a polymer can be exchanged with hydro-
gen atoms on nearby water molecules. The rate of exchange is pH dependent and
influences the measured relaxation rate. A relaxation-pH relationship arises that is
used as a pH sensor in Chapter 5. The mechanisms are discussed in their respective
chapters.
2.1.3 Hardware
Typically, in pulsed NMR, a single coil generates an oscillating magnetic field to
manipulate the nuclear magnetization and also detects the NMR signal. A radio
frequency (RF) switch inside the NMR spectrometer (KEA2, Magritek) alternately
connects the coil to a power amplifier to generate the pulses and to a sensitive
preamplifier to receive the echoes. The pulses typically last less than 10% of the
overall duration allowing ample time for the oscillation to die down and for the
switch to connect the preamplifier to detect the NMR signal[26, 27].
Two permanent-magnet systems are used in the experiments described here. A
benchtop relaxometer (Minispec mq-20, Bruker) is used for testing samples in stan-
dard 5 mm glass tubes. The samples are inserted through a port in the top of the
instrument and sits between two magnets. The arrangement creates a relatively
uniform magnetic field with a Larmor frequency of 19.95 MHz.
A second system is a single-sided magnet (NMR-MOUSE, Magritek, Wellington, New
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Zealand) that measures samples that are outside the instrument. The field, which
runs parallel to the surface, decreases with distance away from the surface. The
sensitive region is a flat sheet of sample approximately 250 Pm thick. This magnet is
particularly useful for measuring samples that won't fit into a traditional instrument.
The magnet arrangement is shown in the cutaway view in figure 2-3. The field
has a built in field gradient that allows the slice selective measurement. However,
this gradient adversely affects the transverse relaxation measurements. Molecules
diffusing along the direction of the gradient experience a changing Larmor frequency
and a random accumulation of phase. The CPMG sequence cannot fully compensate
for this phase accumulation, and the measured T2 is significantly lower than on a
homogeneous field magnet.
The figure also shows a rapid NMR screening system, dubbed the AutoNMR, that is
designed to measure samples in standard plate format. A modular frame connected
to a 3-axis motion stage allows for up to 168 samples to be measured sequentially. A
circulating water bath maintains a constant magnet temperature to avoid a drift in
the field strength over the course of a day. Custom software controls the robot and
programs the pulse sequences.
2.2 Resonant Circuits
It is merely coincidence that a resonant circuit is used to detect the nuclear magnetic
resonance signal. An untuned coil can measure the signal, but a circuit with a
resonance frequency equal to the Larmor frequency greatly improves the signal-to-
noise ratio[47, 48]. The inductor-capacitor circuit acts as a filter that rejects all
signals except those at the frequency.
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Figure 2-3: Plate format NMR (left) combines a commercially-available single-sided
NMR probe with a 3-axis robot. The NMR MOUSE measures a thin slice above the
surface thanks to its unconventional magnet arrangement shown on the right.
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A capacitor, C, is connected with an inductor, L, in series as shown in figure 2-4. A
resistor, R, captures the resistance of the inductor. This RLC circuit has a resonant
frequency,
WO (2.9)VLOU
A sinusoidal driving current at the resonant frequency, i(t) = sin wt, will cause
R
iL
T_ C= 7 
L
Figure 2-4: An RLC circuit models the capacitor-inductor circuit with the resistor
representing the losses in the inductor. At very low frequency the resistance is R,
while at high frequency the capacitor shorts out the current source.
an oscillating current inside the inductor that increases in amplitude over time as
shown in figure 2-5. The energy from the source current slowly builds up inside the
resonant circuit. The energy is stored in the electric field of the capacitor when vc(t)
is maximum or in the inductor's magnetic field when iL(t) is maximum. Energy is
dissipated in the resistor as the current flows in the circuit. The current and voltage
build up until the energy dissipated in each cycle equals the energy supplied by the
source. The quality factor, Q, is defined as the ratio of stored energy to dissipated
energy and roughly corresponds to the number of cycles before the oscillations die
down once the power is turned off. It also represents a measure of voltage or current
gain. The system will always be driven at a fixed frequency, and, thus, it is most
convenient to look at the frequency response of the resonator. The peak in the
Bode plot (figure 2-6) shows the resonance behavior (w = wo) very clearly as a tall
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Figure 2-5: Response of the RLC circuit to a current input
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peak. Low frequency signals flow through the inductor, whereas high frequency input
signals are shorted by the capacitor.
The oscillating magnetic field inside the coil creates a radial gradient in the current
density according to Faraday's law [49, p.3]. Solving in cylindrical coordinates yields
a diffusion equation in the magnetic field H, of the form:
1 d
-r J(r, w) = H(r, w), (2.10)
pI-wr dr
d Hd . = J. (2.11)
dr
Equation (2.11) shows a characteristic 1/po-wr drop off in the current density per-
pendicular to the coil axis. The current flows along the inner surface of the coil. The
concentrated current flows over a narrower cross-section of wire, and the resistance
will be higher than the length and conductivity would predict. The equations are
solved numerically using finite element software (COMSOL v. 4.3a, COMSOL Inc.,
Burlington, MA). The simulation calculates the field generated by a coil as well as
its circuit model parameters. The field plots of figure 2-7 correspond to the model
parameters in table 2.1.
The current density distribution inside the wires is shown in figure 2-8 at 2 MHz
and at 20 MHz. The current is spread out throughout the wire's cross section at low
frequency, but it becomes more concentrated near the inner surface as the frequency
is increased.
50
* I I I I I m u
Wo
Frequency
Figure 2-6: Frequency response of an RLC circuit
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Figure 2-7: Two dimensional simulation of magnetic field in cylindrical coordinates
y - . A 20 turn coil is modeled with 1 A current flow. The field lines show the
direction of B, and the color represents the magnitude of the y directed field.
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Figure 2-8: Two dimensional
cylindrically symmetric about
cross section of current distribution. The images are
the left side of the page. The coil has a larger resistance
at high frequency because the current flows mostly on the inner surface of the coil.
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2 MHz
0
0
0
40 pm
Parameter Value Description
fo 20 MHz frequency
N 20 number of turns
deoil 1.8 mm coil diameter
rwire 40 pim wire radius
s 92 um turn spacing
I 1 A current
L 590 nH inductance
R 1.7Q a.c. resistance
Q 44 quality factor
B I(0,0) 9 mT field at the center
Table 2.1: Simulation parameters and outputs for a 20-turn coil.
MIL1 L2 V2
Figure 2-9: Mutual inductance represented in a circuit diagram.
2.3 Mutual Induction
Mutual inductance from a circuit perspective is the voltage induced in one conductor
as a result of a changing current in a second conductor. The circuit diagram repre-
sented has two inductors, L, and L 2, with a mutual inductance between them, M,
as shown in figure 2-9. Four equations relate the currents through the two inductors
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to the voltages across them:
diiVi = L, di (2.12)dt
di2V2 = L2 di (2.13)dt
dii
V2 = M12 (2.14)dt
di 2V = M21 dt. (2.15)
Calculating the mutual inductance between two coils (see figure 2-10) requires knowl-
edge of their geometry and relative orientation. Faraday's original experiments
showed that a changing magnetic flux through a wire loop will induce a electromotive
force around the loop. The changing magnetic flux is generated by the alternating
current in a nearby coil[50]. Expressed mathematically the voltage in the loop is
given by,
dtS= dt , (2.16)
where 1 is the magnetic flux through the loop. If this flux is generated by current,
i, flowing in another conductor, then the mutual inductance is
M- -. (2.17)
The flux can be calculated by integrating the magnetic flux density, B, over the
surface, S, bound by the loop
=J -f.BdS, (2.18)
S
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Figure 2-10: The field generated by a changing current in one coil induces a voltage,
v2(t) = -Mi, in a nearby coil.
where A is the normal to each differential surface element, dS[38]. This approach has
two drawbacks. The field, B, is calculated using the Biot-Savart equation at each
differential surface element. This is computationally expensive because the magnetic
field would need to be calculated at many points in the three dimensional space
bound by the second coil. The second drawback is that it is not obvious where there
the surface, S, lies.
The magnetic vector potential offers a much faster and cleaner approach. Conven-
tionally denoted by A, it is related to the magnetic flux density as follows,
V x A = B. (2.19)
Stokes' theorem provides a way of converting the surface integral of B into a line
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B1j
integral of A, such that,
Ji -V x AdS= A -dl (2.20)
where 1 is the line bounding the surface S[51]. That line is the coil through which
we want to calculate the flux. The vector potential from a line current, C, at a point
in space, , is given by,
A0p Idl
A(--)= , (2.21)
C
where r is the distance from the point ' to the point along C [38].
The mutual inductance between two coils can be calculated by integrating the vector
potential A along the second coil C2. Combining Equations 2.17, 2.18, and 2.20
yields,
M = A -dl) (2.22)
C 2
which combined with equation (2.21) gives,
/10 IdliM = j _. -d12 (2.23)
C2 C1I
where r'j and r are points along C1 and C2. The circular integrals can be omitted
knowing that C1 and C2 will be closed loops when connected in a circuit. Rearranging
the terms yields a simplified form,
M= PO d1 _ d1 (2.24)
47r craM- r2
C2 C11
The calculation of M is now reduced to an integration over two known paths. The
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subscripts are interchangeable without any change in the form of the equation. This
symmetry proves that there is only one mutual inductance between two coils.
Many papers exist that analytically solve for M. The simplest configuration involves
two circular loops, and the calculation involves using parametric tables[52]. There
are six degrees of freedom associated with the relative position of two wire loops of
arbitrary shape. The simplest approach is to calculate the integral in equation (2.24)
numerically as described in Appendix B. This method is extremely fast even on a
modest computer.
Summary
This chapter introduced three topics that will be combined to perform wireless NMR
measurements inside the body. NMR contrast agents are exploited to give chemically-
sensitive relaxation rates. The signal is contained in a very narrow band around the
Larmor frequency and is efficiently detected with a resonant coil, which acts as a
band-pass filter. Chapter 3 will introduce two coils linked through their mutual
inductance. The NMR measurement is performed inside the sensor coil that is im-
planted in the body. The reader coil resides outside the body and provides the
connection to the spectrometer.
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Chapter 3
Wireless NMR
The wireless NMR system consists of two distinct components: a sensor that is
implanted in the body and a reader that resides outside the body. Both the sensor
and the reader contain a resonant coil, and they are linked to each other through their
mutual inductance. The NMR measurement is performed only on the contents of the
sensor with very little interference from the surrounding tissue. This chapter presents
the theoretical framework for wireless NMR detection with special considerations
made for measurements in living tissue. The design specifically addresses the precise
manufacture of large quantities of sensors that are needed for in vivo testing.
3.1 Magnetic field amplification
A sinusoidally varying magnetic field induces a voltage across a coil. If that coil is
part of a resonant circuit tuned to the field's oscillation frequency then there will be
a gradual build up of current in the coil. Unlike the directly driven resonator shown
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in Figure 2-5, the transfer of energy is achieved wirelessly.
The simplest case models a small coil, Ls, located at the center of a larger coil, LR.
The small coil has a finite resistance, Rs, and is tuned with a capacitor, Cs, to a
resonant frequency, wo = 1/ LSCs. The large coil is driven by an infinite impedance
current source and is not tuned. The time varying current is given by,
iR(t) = eiWOt, (3.1)
where j = V/*I. The mutual inductance between the two coils results in an induced
voltage in the second coil,
d
Vs(t) = M- e3ot = jWoMeo t . (3.2)dt
The circtui has an impedance equal to R on resonance. The current in secondary
coil is given by,
is(t) = vs(t) _ jWoMe *. (3.3)
R R (.
The two coils will each contribute to the magnetic field in space. The total magnetic
field, represented in cylindrical coordinates, is calculated by superposition,
B(r, y, #, t) = is(t)Bs(r, y, 0) + iR(t)BR(r, y, #), (3.4)
where P refers to the field generated by unit current in each coil. The field along ^
is the most relevant for an NMR experiment since the static magnetic field, BO, is
directed along 2. Substituting for the currents in Equation (3.3) and Equation (3.1),
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the total field is given by,
By (r, y, t) = JWo MWOt sy(r, y) + ew otBRy(r, y), (3.5)
where components along q are ignored because of cylindrical symmetry. It is also
convenient to multiply by e-oOt to eliminate the explicit time dependence. The
sinusoidal steady state field is given by,
_jwoM
BY(r,y) = R Bsy (r, y) + BRy(r, y). (3.6)
Taking the real and imaginary parts of By separately reveals that the two coils are
out of phase with each other:
Re [B. (r, y)] = BR,(r, y); (3.7)
Im [B.(r, y)] - WRjisy(r, y). (3.8)
Figure 3-1 shows a cross sectional field map of a 40 turn coil of diameter 0.92 mm
inside a 14 mm, 12 turn coil. The unit current field strengths are 12 mT and 0.36 mT
respectively. The mutual inductance between the two coils is 380 nH. The smaller
coil's resistance is 3 Q. The field amplification for this configuration is,
wo MR- 15sY(0,7 0)HB- = ~ = 52. (3.9)BRy(0, 0)
The quality factor of the small coil, Qs = woLs/Rs equals 49. The coil quality factor
can therefore serve as a first order approximation to the field gain.
If the excitation frequency departs from the sensor's resonant frequency, w , wo,
61
Re[B.] Im[B.J
I+
B
4_1
Figure 3-1: A large field amplification occurs if a coil is excited on resonance.
then the field strength inside the sensor is reduced. The bandwidth is determined
by the sensor coil's quality factor as shown in Figure 3-2.
Two key advantages derived from the field amplification apply to an implantable
sensor. First, the field gain points directly to a boost in the signal-to-noise ratio.
Second, the NMR measurement is almost entirely localized to the material inside the
sensor. The very low field outside of the sensor implies that very little signal will be
detected there. The remainder of this chapter deals with the practical implementa-
tion of wireless NMR.
3.2 Circuit model
The spectrometer alternately connects the probe to a power amplifier (transmit
mode) and a preamplifier (receive mode). Two circuit models are used to describe
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Figure 3-2: The field generated inside the sensor is greatly enhanced when the sensor
is excited at the resonance frequency by a current flowing in the reader coil.
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the transmit mode and the receive mode separately. The circuit abstraction will yield
input-output transfer functions that are used to tune the entire system and to model
the signal-to-noise ratio of the experiment. A two-dimensional finite element model
calculates the coil parameters, and a three-dimensional computation of the mutual
inductance captures the geometric orientation of the two coils. The capacitors are
then chosen to maximize the signal-to-noise ratio of the experiment.
Transmission lines are omitted from the circuit analysis because the length is sig-
nificantly shorter than the wavelength. A 20 MHz wave on a coaxial cable with a
propagation velocity equal to 70% the speed of light in vacuum would have a wave-
length, A ~ 10 m. The cable connecting the coil to the spectrometer is 0.3 m long, so
no wave effects are modeled. The coaxial cable will introduce a small capacitance,
but this will be included in the two variable capacitors on the reader probe.
3.2.1 Transmit mode
The circuit diagram in Figure 3-3 shows the transmit path. The spectrometer power
amplifier is modeled as a voltage source with an impedance RIN =50 Q. Maximum
power transfer is achieved when the probe impedance matches the source impedance.
The two capacitors CM and CT will be selected to ensure power matching. The two
resistors capture the losses in the coils; whereas, the capacitors are assumed to be
lossless.
The coupled probes are modeled as a feedback system, which is shown in the block
diagram of Figure 3-4. The current flowing in the sensor coil, Ie, is the critical circuit
parameter during excitation and is placed at the output. The input is the voltage
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Vs Ls Cs
-F' T
3-3: Transmit path showing a 50 Q voltage source connected to the reader
The resistors model losses in the coils.
, 
VI
Vr + YR -jWM Ys Is
Figure 3-4: Block diagram of the coupled probes. Solution of the feedback loop gives
the current in the sensor coil.
across the reader coil, V. The current through the reader coil is,
Ir = VYR, (3.10)
where the reader coil admittance is
1
(3.11)jWLR + RR
The resulting magnetic field induces a voltage across the sensor coil, V, = jWMI,. A
current, I = YsV, flows through the sensor circuit that consists of a series connected
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RIN
VIN v
Figure
probe.
Y
capacitor, inductor and resistor. The sensor admittance is
Ys = 1/Zs = (jwLs + R + 1/jwCs) 1  (3.12)
where 1/V/LsCs = wo. The feedback loop arises because the sensor current induces a
voltage across the reader coil V- = jwMI, that opposes the driving current. Solving
the block diagram gives
- iWMYRYS (3.13)
V, 1 +w 2 M 2 YRYs
that can be used to calculate the sensor current as a function of the input voltage
for any two-coil system.
It is convenient to calculate the admittance Ir/V when the two coils are coupled
together. The current in the reader coil, I, is the output of the YR block on Figure 3-
4. The feedback loop still applies, but the block diagram is rearranged to put I, at
the output. Solving for that node yields a coupled-probe admittance,
Ir YR
V 1 +W 2M 2YRYs'
where the denominator is the same as in Equation (3.12), but the mutual inductance
is absent from the numerator. If M = 0 then YCp = YR, which is the single-coil case.
The coupled admittance, YCp, simplifies the circuit to look like a single-coil NMR
probe (Figure 3-5).
The tuning and matching capacitors will transform the impedance, ZCp, to equal
the source resistance and maximize the power transfer from the amplifier. The total
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Figure 3-5: Simplified transmit path with the admittance YCp representing the couple
reader-sensor. A single-coil NMR probe has YCp = (R + jwL)-'.
complex impedance from the point of view of the power source is
1 1
Z = +
jWCM jWCT + YCP (3.15)
The matching capacitor adds only an imaginary component. The tuning capacitor,
CT, must be chosen so that the real part of the second term equals the source
impedance at the resonant frequency:
Re [ + ]jWOCM jWOCr +YCP{W0 ] Re [ JOCT + YCP(w 0 ) - Zin- (3.16)
Solving for CT yields
Im [YCP] + Re[YCP] /Zin - Re [Ycp] 2
WO (3.17)
and Equation (3.15) can be rewritten as a sum of real and imaginary components:
Z =WM + jIm [.+ Zn (3.18)WCM jWCT + YCP
The imaginary parts must sum to zero so that Z(wo) = Zin. The capacitance CM is
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the only unknown and is found by solving
=Im . (3.19)WOCM [JWOCTYCP(WO)
The tune and match capacitors can be calculated for any pair of coils in any ori-
entation. The importance of having the reader and sensor tuned at the resonant
frequency cannot be overstated. The tuning and matching capacitors are absolutely
necessary to achieve a workable signal-to-noise ratio. Figure 3-6 shows the field inside
the sensor coil when driven by a resonant (tuned) reader probe versus an untuned
reader.
3.2.2 Receive mode
The spectrometer connects the probe to the preamplifier to detect the NMR signal.
The circuit diagram is shown in Figure 3-7. The NMR signal appears as a voltage
across the sensor coil, VNMR, and is on the order of 10-6 V. This is weak enough that
the thermal noise originating in the resistive elements must be taken into considera-
tion. The noise voltages, (vS) and (VN,R), represent the noise in the sensor coil and
the reader coil respectively. The signal, VNMR, and the noise, VN,S, both originate in
the sensor coil, and they cannot be distinguished from one another. The measured
voltage, when the receiver is turned on, is
v(t) = a [VNMR(t) + VN,S(t)] + /vN,R(t), (3.20)
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Figure 3-6: Simulation of the field inside the sensor coil as a function of distance
from the reader coil. A tuned reader coil increases the field inside the sensor coil
more than 20 fold.
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Figure 3-7: Signal reception path. The NMR signal appears as a voltage across the
sensor coil. Resistive losses in the coils are modeled as noise sources.
where a and / are gain terms to be calculated. Separating the signal terms from the
noise terms yields the signal-to-noise ratio,
SNR = avnmr
a (V2,S) + 2 (viR)
(3.21)
where the best case scenario is not zero noise, but rather SNR = VNMR/ (2,S)_ This
is achieved if the sensor noise is the dominant noise source, that is, if
aV(vn2,S) > /3 (vn2,)_ (3.22)
A well shielded system will be limited by thermal noise, which is a fundamental
physical phenomenon. A resistor, R, at an absolute temperature, T, has a frequency-
independent noise spectral density
V2 =4kBTR, (3.23)
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where kB is the Boltzman constant [53]. The time-averaged noise, (v'), depends on
the receiver bandwidth [54]. If the resistor is connected in a circuit, a noise current
will flow that is given by
.2 y2 kBTR 0y2(W)dW, (3.24)
where Y is the circuit admittance [55]. The resonant circuit acts as a filter with
a voltage transfer function, H(w). The voltage noise through a transfer function
becomes,
V2 = 2 kBTR H2(W)d. (3.25)
The two relevant transfer functions for calculating the noise in Equation (3.21) are
Hs(w) and HR(w). These capture the voltage at the receiver due to a voltage in
the sensor coil and the reader coil respectively. The NMR signal is calculated using
Equation (2.4). This information is used to estimate the signal-to-noise ratio for any
coil configuration.
The importance of the tuning and matching capacitors for the transmit mode ap-
plies also to the receive mode. Figure 3-8 shows the NMR signal received by a 14 mm
diameter reader as it is moved away from a 2 mm sensor coil. The signal strength re-
ceived by the tuned reader is stronger even at 50 mm away from the remote coil. The
sensor noise is also amplified, but the resulting signal-to-noise ratio is still improved
by a factor of 200. Schnall and coworkers implanted a large resonant coil inside
an animal to improve the image resolution in MRI. The authors used an untuned
'sniffer' coil outside the animal in receive mode only. The MRI volume coil was used
for excitation [56]. A resonant reader would have enhanced the sensitivity by several
orders of magnitude.
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Any applications with coupled coils should have both coils tuned to the same reso-
nant frequency. The power transfer during a transmit mode is maximized and the
signal-to-noise ratio during reception are both increased substantially with coupled
resonators. This section focused on wireless NMR, but the enhancement applies to
any application using coupled coils: the transmit pulse can be used to power a device
remotely, and the receiver circuit applies to any signal generated inside the remote
coil.
20-
18.5-
tuned reader
-D
S 10-
untuned reader
30 nV
0
0 25 50
Axial displacement (mm)
Figure 3-8: A tuned reader coil ensures enhanced reception of the NMR signal.
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3.3 Design considerations
Designing an NMR probe for an implantable sensor introduces a unique set of re-
quirements. The outer diameter of the sensor must match the bore size of a biopsy
needle, and all materials must be suitable for implantation. The reader coil is de-
signed for measuring through living tissue, which is conductive.
3.3.1 Sensor length
The sensor should be between 4 mm and 10 mm in length. The minimum length is
the smallest practical amount of sample plus the length of the capacitor. The length
involves a trade-off between sensitivity and response time. A large sample will give a
more sensitive device but increases the time it takes for the analyte to diffuse into the
chamber. Radial fluid access would decouple sensitivity and response rate. Allowing
fluid access from the sides, however, requires a wider coil pitch, which will decrease
the sensitivity. The better choice would be to add fluid access from both sides to the
response time by a factor of four.
The coil was chosen to be approximately 4 mm long, making the sensor 6 mm long
with the capacitor. A two dimensional field map is shown in Figure 3-9. The coil
length is four times the radius and results in a large sensitive volume in the center of
the chamber. The outlined box below the coil is the capacitor pocket. The overlaid
contour map shows the magnetization projected onto the transverse plane after a 900
pulse is applied. The signal strength immediately outside of the device is 50% and
drops off rapidly with distance. Multi-echo sequences will progressively eliminate
the signal from outside the sensor because the refocusing pulses are also ineffective.
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Figure 3-9: Field map of sensor coil showing high degree of uniformity in the sample
chamber. The contour lines represent M.,/Mo, the projection onto the transverse
plane following a 90' pulse calibrated to the center of the chamber.
3.3.2 Wire diameter
Previous work suggested that the overall length of the coil determines the signal
strength [57]. The basic argument is that there is a fixed current density in the
copper wire. This is indeed the case for a fixed sample diameter. However, a sensor
must fit through a biopsy needle and has a fixed outer diameter, and thinner wire
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allows for a larger sample chamber. The chamber walls are three wire diameters
smaller than the sensor diameter; wrapping the coil adds two wire diameters, and
returning the wire to complete the circuit adds a third. A 2.2mm diameter sensor
with a 4 mm long chamber and a coil wound of 32 American Wire Gauge (AWG)
wire will have a chamber volume of 6mm3 . This volume can increase to 10mm if
40 AWG wire is used instead. Figure 3-10 shows the simulated signal-to-noise ratio
from sensors with increasing wire diameter. The first case fixes the sample diameter,
and the second case fixes the sensor diameter. Thinner wire is better even for a
fixed sample size. The current flows along a thin layer on the inner face of the coil.
Thinner wire packs more copper into that region, yielding a modest improvement.
3.3.3 Sensor diameter
The sensor was designed for implantation through an 11 gauge needle. Four sensors
were fabricated with different diameters to explore the lower practical limit on sensor
size. The capacitor pocket was not changed to investigate just the size of the chamber
and coil (Figure 3-11). The sensors were tested in a 0.47 T homogeneous field magnet
(Bruker mq-20). The uniform field ensures that the entire sample contributes to the
signal rather than a slice through the center. The signal strength shown in Figure 3-
12 is normalized to the 2.2 mm sensor on the single-sided magnet. The signal-to-noise
ratio is approximately 10 times large for a sensor in a uniform field. A 1.6 mm sensor
could be implanted through a 14 gauge needle. The thinner wire diameter becomes
increasingly important for small diameter sensors. Simulations over a wider range
of sensor coil diameters (Figure 3-13) shows a similar trend. The highlighted point
corresponding to needle gauges below 11G. The largest possible sensor should be
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Figure 3-10: The signal-to-noise ratio as the wire diameter is increased. The smallest
possible wire diameter will maximize the signal-to-noise by increasing the sample
volume. The coil length is fixed and the wire is wound as compactly as possible;
many more turns of the finer wire are needed to fill the length.
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Figure 3-11: Photograph of sensors with smaller diameter coil and chamber to in-
vestigate the practical lower limit on sensor size.
10 -
Relative signal
strength
0
0
1------------0-------*--------
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0
Uniform field " Current system
0
1 2
Sensor diameter (mm)
3
Figure 3-12: Signal strength versus sensor diameter normalized to the 2.2 mm sensor
on the single-sided magnet. The largest sensor for a given application gives the
strongest signal.
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built for the application. The impact of wire diameter becomes even more critical
for smaller sensors. Every effort should be made to maximize the sample volume.
10-
Cn 1
C.)
bCo
0.1-
0.25 0.92 2.25
Sensor coil radius (mm)
Figure 3-13: Simulated signal-to-noise ratio versus sensor diameter. Increasing the
sensor volume increases the signal-to-noise ratio, but the gains are modest as the
sensor becomes very large.
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3.3.4 Reader coil diameter
The reader coil design is constrained by the tissue surrounding the device. A sensor
implanted with a biopsy needle will be oriented along the direction of implantation.
The reader coil should also be oriented with its axis along that direction. This may
be perpendicular to the skin. The implantation in mice and rats, however, is along
the axis of the body parallel to the skin's surface. The reader probe for rodents is
designed so that the animal can fit through the coil. Mice can be restrained in a
26 mm diameter tube that allows for oxygen and anesthetic gas to be introduced.
The reader coil is 28 mm in diameter to fit the restraining tube. The same probe
is used to measure sensors implanted in the gastrocnemius (calf) muscle of a rat by
inserting the leg into the reader coil. Practical considerations have fixed the inner
diameter of the coil, but the number of turns and length are free variables to be
explored.
3.3.5 Number of turns on the reader coil
Increasing the number of turns on the reader coil decreases the received NMR signal.
Figure 3-14 shows the simulated signal strength from a sensor inside the reader as a
function of number of turns on the reader coil. The sensor remains the same, thus
any increase in the NMR signal will also apply to the noise from the sensor. The
overall signal-to-noise ratio will therefore be determined by the noise originating in
the reader coil.
A reader with more turns will have a greater resistance and inductance. The re-
sistance increases approximately linearly with the number of turns, N, but the in-
ductance increases by approximately N 2 . The resulting higher coil quality factor,
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Figure 3-14: The received signal amplitude decreases as the number of turns on the
reader coil is increased.
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Q = wL/R, improves the filtering of the noise. Figure 3-15 shows that the reader
noise dominates when the reader coil has fewer than 6 turns. The resultant signal-
0.5-
total
noise
S0.25 "
CdS
%% reader
device noise
noise \'.
0-
2 10 20
Number of turns on reader
Figure 3-15: Thermal noise at the receiver due to losses in the reader and sensor
coils. The thermal noise from the reader coil dominates the sensor coil noise when
the reader coil has fewer than six turns. If thermal noise is the only noise source
then the reader coil should be designed so that the sensor noise is dominant.
to-noise ratio is shown in Figure 3-16. Paradoxically, a higher sensor to receiver gain
does not improve the overall signal fidelity.
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Figure 3-16: Considering only the thermal noise, the signal-to-noise ratio increases
with the number of turns on the reader coil.
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3.3.6 Noise and EMI
Figure 3-16 corroborates work on inductively coupled coils for NMR spectroscopy.
The high-field magnets increase the signal, and the excellent shielding ensures that
the sensor coil is the dominant source of noise [58]. The question is whether the same
applies to a low-field NMR measurement through tissue.
The signal must be strong enough to be digitized efficiently. The analog to digital
converter expects the incoming signal to span a certain voltage range. A 16 bit
digitizer divides the anticipated signal span into 65,536 discrete levels. Each data
point is rounded to its nearest level. If the actual signal is weaker and spans only a
fraction of the range, the rounding becomes significant and is referred to as quanti-
zation error [59]. The signal must be strong enough to be detected, regardless of the
signal-to-noise ratio.
The preamplifier adds a constant voltage noise plus current noise that is propor-
tional to the probe impedance. There is an optimal probe impedance that minimizes
the preamplifier noise [32]. Ideally, the spectrometer is designed with the receiver
path optimized for noise and the transmit path optimized for maximum power trans-
fer [60]. Most spectrometers are made of discrete components that are all designed
with 50 Q impedance. The spectrometer (KEA, Magritek, Wellington, New Zealand)
was connected to a 50 Q resistor recorded a noise level of 0.3 pV. Figure 3-15 suggests
that the reader coil noise would dominate on a two-turn coil but that the amplifier
noise might dominate otherwise.
The final consideration is electromagnetic interference (EMI). The sensor will be im-
planted in living tissue that has a conductivity -1 S m-. The conductive tissue acts
as an antenna picking up noise from the environment. Shielding will eliminate EMI,
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but shielding a patient is impractical and would defeat the purpose of a portable sys-
tem. The noise level was measured with a mouse inside the reader coil. The recorded
level varies from 0.8 pV to 1.5 11V, which is greater than the thermal noise.
The signal-to-noise ratio is fundamentally limited by thermal noise, but additional
noise sources dominate when measuring in living tissue. The best signal-to-noise ratio
is achieved by maximizing the voltage gain between the sensor and the receiver.
3.3.7 Reader coil length
Figure 3-17 shows a contour map of mutual inductance versus position with the
sensor parallel to reader axis. The reader is a two-turn loop centered at the origin.
The bold contour lines outline a region where the mutual inductance is within ±1%
of the value at the origin. The diagram is rotationally symmetric about the X axis.
Inserting a space between the two turns increases the overall reader length and
reduces the maximum mutual inductance. However, the uniform region over which
the sensor can be moved without requiring retuning becomes larger. The sensor can
be measured anywhere in this region even if the precise location is unknown. A coil
with one radius separation between the two turns is known as a Helmholtz coil. The
expanded +1% region is shown in Figure 3-18.
3.3.8 Tissue conductivity
The simulations so far have assumed that the sensors are in free space, not in conduc-
tive tissue. This assumption is certainly valid for benchtop tests, but the sensor will
be implanted into living tissue that has an electrical conductivity between 0.2 S m-1
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Figure 3-17: Mutual inductance between a two-turn reader coil and a sensor coil
versus position. The diagram is rotationally symmetric about the X^ direction. The
thick line represents the volume over which M changes less than 1% from the origin.
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Figure 3-18: Mutual inductance contour map when the two turns of the reader coil
are separated by one radius. The 1% region is significantly expanded compared to
Figure 3-17.
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and 0.7 S m-1 [61]. The conductivity is responsible for pickup of noise from the en-
vironment as discused in Section 3.3.6, but there is inherent loss in the tissue.
The oscillating field generated by the reader coil induces a current in the conductive
fluid inside the body. This current generates a field that opposes the reader's field.
The moving charges experience a resistance that will also be a source of thermal
noise. The advantage of the implanted probe is that only a weak field is needed to
generate a high field inside the sensor (see Figure 3-1).
Figure 3-19 shows the field inside the sensor and the reader coil's effective resistance
as a function of conductivity at 20 MHz. The field does not experience a significant
drop off until the conductivity is well above that of normal tissue.
A higher Larmor frequency is almost always preferred in NMR. Both the magneti-
zation (Equation (2.1)) and the induced voltage (Equation (2.4)) are proportional
to wo. Field strengths of 2 T to 3 T are available from permanent magnet systems
but only for small sample sizes. The loss at high frequency is more pronounced and
would be noticeable even in moderately conductive samples. Figure 3-20 shows that
a lower frequency probe performs better for very high conductivity samples.
3.4 Practical considerations
Section 3.2.1 showed that the two variable capacitors on the reader probe can match
virtually any coil configuration to the source impedance. Correctly tuning the probe
becomes tricky when the sensor is hidden inside tissue.
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Figure 3-19: The field strength inside the sensor is virtually unchanged over the range
of conductivity expected inside the body. The increased resistance of the reader coil
captures the loss in the conductive medium.
87
I
43
1-
16
4.1
0
10-2 101
c- (S/m)
Figure 3-20: Plot
Higher frequency
media.
of sensor field versus the conductivity of the surrounding medium.
operation is generally preferred except in very high conductivity
88
10-1 100 102
100 MHz
10 MHz
I MHz
103
3.4.1 Tuning frequency
If the sensor resonant frequency, ws, does not equal the Larmor frequency, wo, the
reader can still be tuned and matched to 50 Q. Figure 3-21 shows how the signal-
to-noise ratio varies over a ±20% mismatch between the sensor frequency and the
Larmor frequency. Small variations in frequency have very little effect on the signal-
to-noise-ratio.
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Figure 3-21: Plot of signal-to-noise ratio as a function of mismatch between the
sensor resonant frequency and the Larmor frequency. Maximum SNR is achieved on
resonance, but slight deviations in the sensor's resonant frequency do not matter.
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The main challenge with tuning is that it is possible to tune when the sensor is not
in the optimal position. The tuning will give the local maximum SNR, but not the
global maximum. It would be helpful to be able to tune the reader without a sensor
present to ensure that when the sensor is in the right place the optimal signal-to-
noise ratio will be achieved. Figure 3-22 shows a scheme whereby the reader is tuned
to a lower frequency without the sensor present. The sensor is then positioned at
the center of the reader coil, and the signal-to-noise ratio is simulated. The precise
frequency offset will depend on the coils, but for this configuration the maximum
possible SNR is achieved if the reader is tuned such that Z(w = 0.9wo) = 50Q without
the sensor present. The reader is then moved closer to the sensor until the highest
signal-to-noise ratio is recorded. That is the global maximum, and it is already tuned
optimally.
3.4.2 Misalignment
The reader coil is designed to reduce the effect of lateral misalignment on the mutual
inductance and on the tuning. It is much harder to compensate for angular misalign-
ment, however. The mutual inductance can be reduced to zero if the sensor is at a
900 angle to the reader coil.
A sensor was rotated about 2 in a uniform field to investigate the extent of reduction
in mutual inductance as a result of angular misalignment. Figure 3-23 shows that
the signal amplitude is reduced by approximately 50% when the sensor is rotated by
450 , and a signal is still measurable with a 600 deviation.
If the sensor is rotated to have a component of its axis along the magnetic field direc-
tion, 2, then the effective oscillating field is also reduced to B1,,ff = B1 cos 6.
90
tuned with
sensor
tuned
withou-t
sensor
1
Wtune/wo
1.2
Figure 3-22: The reader coil can be tuned to a lower frequency without the sensor to
maximize the signal-to-noise ratio when the sensor is inserted. The SNR is equivalent
to tuning at the resonant frequency with the sensor inside. This method provides a
way to tune when the precise location of the sensor is unknown.
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Figure 3-23: Measured echo amplitude versus the angle between the reader and
sensor axes. The signal is relatively insensitive to angular deviations less than 20'
and is detectable even with deviations as large as 600.
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3.4.3 Remote measurement
A sensor implanted in a human cannot be measured inside a reader coil, but, in-
stead, the reader coil is pressed up against the skin. This arrangement corresponds
to values of displacement x > 4mm on the mutual inductance contour map in Fig-
ure 3-17. The Helmholtz configuration may not be the optimal coil for a remote
measurements.
The field strength at a distance x from a current loop of radius r can be calculated
using the Biot-Savart equation. The field along X' is
p10I rB(r, x) = 2 r (3.26)
2 (r2±+x2)3/2X
If the implantation depth is known then x is fixed. The optimum coil radius can
be calculated by maximizing B,(r, x) with respect to r. Differentiating and solving
for r in terms of x, the optimum reader diameter for a fixed depth of measurement
is x/v/2. Figure 3-24 shows the field strength inside the sensor as a function of
separation for two different reader coils. A 14 mm radius reader coil is the optimum
coil for measuring at approximately 10 mm depth. A portable system for measuring
sensors in humans could have a set of concentric coils. The appropriate coil could be
chosen based on the implantation distance. Figure 3-24 also hints at a method for
measuring the implantation depth. If the two coils are connected such that the fields
are in opposite direction, then the fields will cancel where their two curves cross.
The mutual inductance to a sensor would be zero at that distance and non-zero
everywhere else. The known depth can then be used to pick the appropriate reader
to perform the measurement.
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Figure 3-24: Field strength inside the sensor at a distance from the reader coil mimics
the human system configuration. A larger radius coil improves the sensitivity at
larger distances. There is an optimum coil radius for each measurement depth.
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Figure 3-25: Photograph of an implantable sensor
3.5 Sensor fabrication
The sensor is designed to be implanted through a biopsy needle. It must retain
sensitivity during its stay in the body and provide useful information that will in-
form a clinician's medical decisions. It should not cause an adverse reaction in the
surrounding tissue both for the patient's well-being and to avoid measuring its own
impact on the tissue.
Biopsy needles are available in a variety of sizes; smaller aspirator needles are less
invasive, while larger core biopsy needles yield a larger sample and better results.
The sensor is designed to fit a standard 11 Gauge needle that has an inner diameter
of 2.3mm. One example of a soft tissue core biopsy needle is the Quick-Coree
Biopsy Needle Set (Cook Medical, QCS-14-9.0-20T) that consists of a needle, a
guide cannula, and a trocar. A photograph of the three parts is shown in figure 3-26.
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Figure 3-26: Core biopsy needle. A trocar facilitates insertion into the body. The
cannula provides a channel through which the biopsy needle can obtain multiple
tissue samples.
The implantation of a sensor into a gelatin phantom is shown in a photo collage in
figure 3-27. The cannula and trocar are assembled together forming an introducer
needle. The physician inserts the needle under image guidance into the region to be
tested. The trocar is removed and the biopsy needle can be inserted through the
cannula to take many samples. This particular model can excise a 20 mm long tissue
sample from up to 9 cm deep into the body. The sensor would be implanted after
the samples are removed.
A more practical tool for testing the sensors is a microchip injector designed for
implanting radiofrequency identification (RFID) tags in pets and livestock. The
injector is normally supplied sterile and preloaded with an RFID tag. Subcutaneous
implantation is fast and painless, and anesthesia is not necessary. The parts of the
injector are shown in figure 3-28. A syringe plunger with an extended arm deploys
the sensor through the needle, while the barrel provides support. The inner diameter
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Figure 3-27: Sensor implantation following a mock biopsy procedure on a gelatin
phantom.
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Figure 3-28: Subcutaneous implantation needle.
of this injector is 2.23 mm.
A 2.2 mm diameter sensor easily fits through either the biopsy needle or the chip
injector. The main components of the sensor are shown in figure 3-29. A plastic
body provides mechanical support to the NMR probe, which is comprised of a coil
and a capacitor. The sample chamber holds the contrast agent, which determines
what the sensor can detect. The manufacturing steps are described in the following
sections.
3.5.1 Machining the plastic body
The body of the probe is machined out of a solid block of polyetheretherketone
(PEEK), a high temperature thermoplastic that is used extensively in orthopedic
medical devices [62, 63]. PEEK has a high enough melting point that the capacitor
and coil can be soldered in place. Direct soldering avoids transfering the fragile
circuit onto the body and increases the yield.
The plastic body is machined using a precision milling center (Model S, Cameron
Micro Drill Presses, Sonora, CA). The mill has a high-speed spindle (E3000C, Nakan-
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Figure 3-29: Key components of implantable sensor
ishi Inc. Kanuma-shi, Tochigi, Japan) that can handle small carbide cutting tools
(Harvey Tool, Rowley, MA). Forty sensors are milled from a single PEEK block
measuring 65 mm long, 40 mm wide, and 20 mm thick. Figure 3-30 shows the first
milling steps. The chamber and coil bobbin are cut as an upright hollow cylinder
with a wall thickness of 50 pm. A small pedestal is milled beneath that will house
the capacitor. The stock is mounted vertically so that the cylinders are on their side.
The capacitor pocket is milled into the pedestal as shown in figure 3-31. Two holes
are drilled to feed through the coil wires. Two relief holes are drilled at the end to
allow air to escape during potting. The completed body is parted from the stock
and is ready for coil winding. It takes approximately one minute of cutting time per
base.
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SIDE VIEW
Figure 3-30: Machining the sensor body and cavity. The cavity is drilled (1-2) and
the coil support bobbin are milled using carbide end mills (3). The lower portion
will house the capacitor and is cut to the final sensor diameter (4).
TOP VIEW
Figure 3-31: Machining the capacitor pocket. The stock is rotated 900, and a pocket
is cut for the tuning capacitor (5-6). Wire through-holes are drilled (7) before the
completed body is parted from the stock (8).
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3.5.2 Winding the coil
The body is supported on a steel rod and mounted on a coil winding machine (Optima
1100, Synthesis Winding Technologies Pvt. Ltd., Bangalore, India). The wire is
fed into the capacitor pocket and secured. The winder rotates the bobbin while
maintaining constant tension in the wire.
The sensors used in vivo had 42 turns of 40 AWG coated copper wire (MWS Wire
Industries, Westlake Village, CA). The wire has a 79 pim diameter copper core with a
3 pm thick polyurethane-nylon coating. Coils are wound with each successive winding
in contact with the previous one to give a wire spacing of 92 pm. The coil is secured
either with a heat gun or a small dot of medical grade cyanoacrylate gel. The wire
is cut from the machine and fed through the opposite wire hole. The body with the
new coil is removed for testing.
3.5.3 Tuning the resonant circuit
Many sensors are required for animal studies, so it is important that they are pro-
duced identically. Precision machining and controlled coil winding are a necessary
first step. Proper tuning will ensure that all sensors have the same resonant fre-
quency.
The coil inductance, Ls, is measured on an LCR meter (SR720, Stanford Research
Systems, Sunnyvale, CA) with the aid of surface mount device tweezers. The induc-
tance is typically 1.2 11H with approximately one percent deviation from the mean.
A suitable capacitor must be chosen to tune each coil.
Surface mount capacitors are the obvious choice for a compact probe. Capacitors
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with the metric designation 1608 measure 0.8mm by 0.8mm by 1.6mm and can fit
perpendicularly to the axis of the sensor. They are supplied in a dispensing roll with
a nominal capacitance tolerance of 10 %. Each capacitor is measured with the LCR
tweezers. The NMR probe is tuned by choosing a capacitor, Cs = 1/(wLs).
The capacitor is loaded into the sensor pocket with the coil wires close to the capacitor
connections. A small amount of solder paste (Quickchip) is applied on either side
and soldered using a temperature controlled soldering iron (Weller W150). The
protruding wires are trimmed leaving a fully functional NMR probe.
The final product will be completely encapsulated in epoxy, but it is helpful to
confirm that the soldering and tuning were successful. A 20 mm diameter, 10 turn
coil attached to a network analyzer (Hewlett-Packard 4396A) measures the frequency
response of the sensor.
3.5.4 Potting in epoxy
The sensor is a fully functional NMR probe after the capacitor is soldered. The sensor
can be tested on the benchtop. Potting in epoxy provides mechanical stability and
insulates the probe from conductive tissue. All sensors are potted in medical grade
two-part epoxy (Loctite M31-CL, Henkel Corporation). Epoxies are chemically inert
once cured and are used to seal electronics in implantable medical devices[64]. This
particular epoxy has a low viscosity and a 30 min work time that make it ideal for
injecting into a mold around the sensor. It can be sterilized using either steam
autoclave or ethylene oxide[65]. It is certified against biological tests (ISO 10993)
that showed no adverse tissue effects after two weeks implantation [66].
The sensors are potted in a two-part acetal mold. The bottom part has four posts
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to align the sensors and prevent any epoxy from filling the sample chambers. The
top part has four 2.2mm holes that will mold the outer surface of the sensor. The
two parts are sealed together and the epoxy is injected through a filling port. The
relief holes inside the capacitor pocket allow any air to escape. The epoxy cures
overnight at room temperature. The mold is separated, and a gentle tap releases
the sensors from the mold. A photograph of the NMR probe is shown in figure 3-32.
The resonant frequency and quality factor of the potted sensors are measured using
the network analyzer. The sensors are washed in a soap solution in a sonicating bath
for 15 min. They are rinsed first in deionized water and then in isopropanol.
Figure 3-32: Photograph of a completed NMR probe. A sensor is made by filling the
chamber with the appropriate chemically sensitive contrast agent.
Precision machining and choosing the right capacitor for each inductor yields a very
tight frequency distribution. Twelve sensors fabricated this way had a mean center
frequency of 15.35 MHz with a standard deviation of 18 kHz (or 0.1%). The average
sensor quality factor was 41, meaning that the devices have a bandwidth of fs/Qs =
380 kHz. Compared to the probe bandwidth, the sensors are identical.
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3.5.5 Filling with the assay material
The contrast agents for pH and oxygen are solids. The sensor chamber can be filled
with the monomers, and polymerization occurs directly inside the chamber. The
plastic shows no cross-reactivity and does not inhibit the reaction.
Liquid based contrast agents, on the other hand, require a membrane to keep them
inside the sensor. The membrane must allow the target to diffuse freely. The car-
diac sensors (Chapter 6) were disc shaped devices with ample area to adhere a
semipermeable membrane. The biopsy implantable sensors would require a minor
modification to the chamber opening to allow a membrane-sealing ring to mechan-
ically seal a membrane. Polyethylene membranes with nanometre sized pores are
sufficiently compliant for snap-fit fixtures and have been used successfully to retain
the nanoparticle contrast agents.
3.6 Reader fabrication
The majority of tests were performed on rodents and a specialized reader was de-
signed to accommodate anesthesia and restraint. The reader coil has two identical
coaxial coils separated by a distance of one radius. The current direction is the
same in both coils to ensure that the fields add constructively in the center. The
bobbin is machined out of acetal copolymer with a diameter of 28 mm. Two turns
of 0.2 mm coated copper wire are wound on each side to form the coil. A tuning
circuit is formed of two variable capacitors (Model 5641, Johanson Manufacturing
Corporation, Boonton, NJ) potted in epoxy. The tuner and coil are both mounted
onto a circuit board. The entire structure slides into a machined metal enclosure
104
that shields and grounds the coil.
3.7 Testing the complete system
The complete measurement apparatus for in vivo studies is built on a mobile cart as
shown in figure 3-33. The anesthesia cart supplies oxygen with 1%-2% isofluorane
gas. The magnet is mounted on a vertical lift with a temperature controlled stage.
The lift adjusts the magnet independently of the reader coil to locate the sensor
within the animal.
The computer and spectrometer (KEA 2, Magritek, Wellington, New Zealand) are
on the middle shelf. Power supplies, the temperature controller, and water pump
are on the lower shelf. The cart, keyboard and (computer) mouse are fully washable
and sterilizable to prevent cross-contamination between animals.
The CPMG experiment outlined in section 2.1.2 can be used to confirm that the
reader-sensor are working correctly. The first pulse in the sequence is increased in
amplitude and the signal amplitude is recorded. The pulse amplitude is attenuated
from a 100 W amplifier. The echo peak is highest when the 90' condition is met. Fig-
ure 3-34 shows the echo amplitude as a function of pulse amplitude. The maximum
echo corresponds to the complete mapping of the magnetization onto the transverse
plane. Doubling the pulse duration reduces the pulse amplitude required for a 900
pulse by 6 dB. A transverse relaxation measurement performed in vivo is shown in
figure 3-35. The data are fit to a form S(t) = Soe-t/T2 to calculate the relaxation
time.
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Figure 3-33: Complete measurement apparatus for preclinical testing.
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Figure 3-34: Verifying the measurement of an echo and scaling with pulse amplitude.
The maximum echo amplitude represents the 900 condition.
3.8 Conclusion
This chapter presented both the theoretical view of wireless NMR as well as the phys-
ical manifestation of an implantable NMR probe. The probe allows high sensitivity
remote measurement of a sample with very little interaction from the surrounding
tissue. MRI is the only other method capable of isolating the signal from a spe-
cific point in space. An implanted NMR probe is ideal as a sensor since only one
measurement is required from the entire sample .
Designing an NMR probe for implantation introduces a unique set of requirements.
The largest sensor should be used for each application. The sensor size should be
as large as the implantation needle, and the thinnest possible wire maximizes the
sample volume and gives the best signal to noise ratio.
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Figure 3-35: Transverse relaxation measurement acquired with an implanted sensor.
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The reader must be optimized both to the sensor and to the target tissue. Small
animals can be inserted into a reader coil, and a Helmholtz-type coil is optimal
as it gives the best field uniformity. Larger animals and humans require a remote
measurement for which an optimum reader radius exists. Loss inside the surrounding
tissue is negligible. The large field amplification inside the sensor reduces the tissue
losses even in extremely conductive media or at high frequencies. This could have
applications both in higher field microimaging or in vivo spectroscopy where the
tissue losses are more severe.
The implantable probe becomes a sensor only with the appropriate chemically sen-
sitive NMR contrast agent. The following chapters present a few possible targets of
interest.
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Chapter 4
Oxygen sensing
Living organisms depend on oxygen, and the overall health of living tissue can be
assessed by measuring tissue oxygenation. A pulse oximeter is included on the cart
that measures a patient's vital signs during any visit to the doctor's office or the
hospital. The oxygen level of blood is calculated by tracking the color change between
oxygenated and deoxygenated blood as the heart beats. This method does not work
in the absence of a pulse or in tissue [67]. Similarly, blood oxygen level dependent
(BOLD) MRI looks at perfusion differences across tissue. The contrast typically
requires careful controls to determine which parts of the brain are activated by the
stimulus [68]. Both techniques are extremely powerful but require known perfusion
models to function. They do not work if blood flow is irregular or restricted.
Poorly oxygenated tissue is a result of poor local perfusion and has no impact on the
oxygen level in the rest of the body. A generic whole-blood test cannot detect the
oxygen state of a specific tissue. That information needs to be acquired directly at
the site of interest. Normal tissue has an oxygen tension of approximately 5kPa or
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40 mmHg in customary units. Tissue below 2 kPa is hypoxic; anything below 200 Pa
is considered severely hypoxic or anoxic [69]. The work in this chapter was performed
in collaboration with Vincent Liu, Yibo Ling, and Syed Imaad.
4.1 Oxygen and cancer therapy
Radiotherapy creates DNA radicals that must react with oxygen to cause damage
that will kill the cell [69]. Oxygenated tumors have been shown to require a lower
radiation dose, while poorly oxygenated tumors are resistant to radiotherapy. Tu-
mor hypoxia is predictive of the patient's outcome [70]. Low oxygen has also been
implicated as a driving force for metastasis [9]. Knowledge of the tumor oxygenation
would guide dose selection prior to treatment. Unlike a needle probe, an implanted
oxygen sensor can be used over the course of therapy completely non-invasively.
The drug tirapazamine is actively being investigated to improve the action of chemother-
apy and radiotherapy on hypoxic cells. Hypoxic conditions reduce the drug to form
free radicals, which are believed to enhance the therapy [69]. However, clinical trials
have not had promising results. A trial of tirapazamine in advanced non-small-cell
lung cancer showed no benefit from adding tirapazamine [71]. A separate Phase III
clinical trial investigated whether combining tirapazamine with cisplatin and radia-
tion would improve outcomes in patients with advanced squamous cell cancer of the
neck and head. The authors concluded that tirapazamine did not improve outcomes
in patients "not selected for the presence of hypoxia" [72]. Tirapazamine is not ex-
pected to work in oxygen-rich tumors. An implanted oxygen sensor could identify
patients with hypoxic tumors for whom tirapazamine is expected to work. The clin-
ical trials could then be repeated in a hypoxia-selected population. If tirapazamine
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were approved for treatment of patients with hypoxic tumors, a measurement of the
oxygenation state of the tumor would be necessary, and an implanted oxygen sensor
could provide that information.
4.2 Oxygen as a contrast agent
Paramagnetic species in solution reduce the longitudinal relaxation time [40, 29].
Molecular oxygen is paramagnetic because of two unpaired outershell electrons and
must often be purged to measure a material's inherent T, [73]. Siloxanes are excellent
hosts for oxygen as a contrast agent owing to their intrinsically long relaxation time
coupled with a high oxygen solubility. A blend of two siloxane materials is used as an
NMR oxygen contrast agent [74]. Polydimethylsiloxane (PDMS) serves as a matrix
to support dodecamethylpentasiloxane (DDMPS). The formulation was developed
through careful study of many different siloxanes. The final choice was a balance
between the long-term stability of the larger molecular weight siloxanes and the high
sensitivity of the shorter chains.
The transverses relaxation rate of a solution of viscosity, 7, at a temperature, T,
containing N ions per cm 3 is given by
1 167r 2 N i( P2) 1 2
T- 15 kT' (4.1
where p is the net magnetic moment of the ion, -y is the gyromagnetic ratio, k is the
Boltzman constant [29, p. 304]. This form is not appropriate for studying oxygen
diffusion in a matrix-embedded material because it is impossible to measure viscosity.
It is, however, possible to measure oxygen diffusivity in a solid either by using NMR
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to track the diffusion of T as the oxygen partial-pressure is adjusted [75]. The
derivation of Equation (4.1) assumes that the ions and solute molecules are spheres
with equal radii and diffusivities. The Stokes-Einstein relation is used to introduce
the viscosity and temperature dependences. The ions are assumed to have point
dipoles in the center, and the effective magnetic moment, p, is calculated assuming
that the particles can only approach each other as close as one diameter.
Oxygen is much smaller than the siloxanes, and the closest distance of approach will
be (ro + rs). The diffusion coefficient of oxygen in the siloxane is also expected to
be higher than the self-diffusion coefficient of the siloxane. The net distance between
two diffusing particles after time T is ~ -2DT. If the diffusivities are very different
then 2D -+ Do + Ds [29]. The relaxation time due to dissolved oxygen is now given
by
1 47r Ny2(p2)
T - 5 (rox + rs)(Do + Ds)
where the explicit temperature dependence is lost. The diffusivity and solubility,
however, will vary with temperature. The material's inherent relaxation is not in-
cluded but will be considered using the relaxation time measurements in the next
section. The equation suggests that the shortest T is achieved in a material that
has a high solubility but low diffusivity.
Table 4.1 has physical data for methyl siloxanes with between two and five silicon
atoms per molecule. Siloxane self-diffusion coefficients were reported in the litera-
ture by McCall and Anderson [76]. Solubility was measured using gas chromatog-
raphy [77]. Oxygen diffusivity was measured by relaxometry as the material was
exposed to different oxygen environments. Calibrating the measured relaxation time
in known concentrations of gas, the oxygen diffusion was tracked by measuring the
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Molecule Ns Mol. mass 02 Solubility 02 Diffusivity Diffusivity
sc g/mol mol/cm 3 [77] x 106 cm/s 2 [76] x 106 cm/s 2 [75]
HMDSO 2 162.4 2.2 20 4.2
OMTSO 3 236.5 1.18 17 2.95
DMTSO 4 310.7 0.71 14 2.14
DDMPS 5 384.8 0.49 13 1.59
Table 4.1:
values are
Siloxane molecule physical parameters and interaction
used in Equation (4.2) to estimate T1 .
with oxygen. The
Full name Molecule T1,N 2 T1,air T1,pred
ms ms ms
Hexamethyldisiloxane HMDSO 7080 2000 2150
Octomethyltrisiloxane OMTSO 5870 1740 1650
Decamethyltetrasiloxane DMTSO 4670 1580 1420
Dodecamethylpentasiloxane DDMPS 3920 1470 1100
Table 4.2: Measured and predicted values of T for siloxanes in air. The sensitivity
is ultimately determined by the very high inherent T values of the material.
T1 across the material. This approach yielded oxygen diffusivities in liquid siloxanes
and matrix-embedded materials. The diffusivities reported for liquids are much high
than the matrix embedded materials and are likely due to convective effects. The
matrix embedded materials will not experience convection, and those diffusivities are
used in the calculations [75]. All measurements were reported at room temperature
(25 0C).
Measured and predicted values for T are shown in Table 4.2. Longer chain siloxanes
have lower relaxation times both in nitrogen and in air. The oxygen sensitivity of a
sensor is determined by the total change in T between the oxygenated and deoxy-
genated states and by the accuracy with which that change can be measured.
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4.3 Oxygen sensitivity
A sensitivity metric for comparing materials must take into account the change in
T1 between high and low oxygen partial pressures as well as the baseline relaxation
rates. The material has an inherent relaxation time, T1, that is reduced to T 1,0
when fully oxygenated. The normalized signal from a saturation recovery sequence
is
S(T) = 1 - e/T1, (4.3)
where T is the time that the material is allowed to recover from zero magnetization.
The signal difference between the deoxygenated and oxygenated states is
AS(T) = e-'/T - e-7/T,o (4.4)
Differentiating with respect to time gives a recovery time, Tmax, that maximizes the
signal difference:
ST1T 1,0  T 1,0
Tmax ln . (4.5)Ti + T1,o T
The total signal change ASmax = AS(Tmax) is
)T1,o _ T,TT 1 ,0 +T1 /TTi,+T1ASmax = TT1 ) - , (4.6)
T1, 0 T1,0
which, if T, >> T 1,0 , simplifies to give,
ASmax Ti - T1,(47)
That is, the metric for maximizing the signal is the fractional change in T1.
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The noise, n, on each measurement is independent of the sample and can be reduced
by acquiring more data. Comparing materials requires a fixed measurement time,
t,. The scan time in a saturation recovery sequence is approximately Tmax such that
the number of scans in a time, tm, is
Nscans - tM. (4.8)
Timax
The measurement can also be improved by acquiring multiple echoes for each inten-
sity measurement. The number of echoes that can be acquired will depend on the
material's transverse relaxation time, T2 , and the echo time, TE. The total number
of echoes will be proportional to T2 /TE. The signal-to-noise ratio will therefore be
given by
SNR oc .tT2  (4.9)
n TmaxT E
The factors tm and TE are chosen arbitrarily, and n is fixed. All three are set to
unity for simplicity. Under the assumption that the inherent T is much longer than
the oxygenated T 1 , the signal-to-noise ratio equation is simplified:
T1R- T1oTSNR oc ' m (4.10)
This metric suggests seeking a materials with the largest possible fractional T change
with long transverse relaxation times. Liquid siloxanes have exceptionally long relax-
ation times, but their volatility limits long term implantation. A covalently bonded
siloxane, instead of matrix-embedded liquid, is worth pursuing because it would have
an indefinite lifetime. Solids can be characterized by exceptionally long T but almost
always have very short transverse relaxation times.
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4.4 Oxygen sensitivity experiments
A blend of 30% PDMS (Sylgard 184, Corning) in DDMPS (Sigma) was used in
the sensors. An amount of curing agent (Sylgard) equivalent to 1/10 the mass of
PDMS was added. A sensor was filled with 10 pl of the siloxane and heated to
80 C for 90 min. The sensor was mounted inside a gas flow tube inside the reader
coil. A gas mixer (Pegasus systems) controlled the fraction of oxygen in nitrogen
flowing at 50 cm 3 min-1 . Intensity data were acquired using a saturation recovery
sequence at a single recovery time, r =600 ms. The sensor responds reversibly to
changes in the oxygen fraction and equilibrates in under 10 minutes (Figure 4-1).
The resulting calibration curve of signal intensity versus oxygen fraction is shown in
Figure 4-2. A linear response is not expected so the intensity is fit to a second order
polynomial representing the series expansion of Equation (4.3). Fitting to this form
yields an oxygen sensitivity of better than 1%. The single-point saturation recovery
sequence is much faster than a full T measurement and captures the dynamics of
the sensor response. The Ti-weighted intensity can be converted to T by solving
Equation (4.3). In vivo experiments require a complete T measurement, because
the equilibrium magnetization will change between experiments.
4.5 Tissue oxygen measurements
Sensors filled with the siloxane blend were implanted in the calf muscle of Sprague-
Dawley rats with a biopsy needle. The tissue oxygenation was modulated by switch-
ing the inspired gas from pure oxygen to air and by restricting the blood flow to
the leg. The former approach monitors the transition to normal oxygenation from a
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Figure 4-1: The oxygen sensor response (top) to changing oxygen fraction in a balance
of nitrogen (bottom). Each condition was maintained for 30 min. A saturation
pulse sequence with 600 ms recovery time yields a very fast Ti-weighted intensity
measurement for monitoring dynamics.
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Figure 4-2: Calibration curve of T weighted intensity versus oxygen fraction in
nitrogen. The error bars are smaller than the marker size.
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hyperoxygenated state, whereas the latter explores a hypoxic condition that mimics
trauma or compressive injury.
4.5.1 Inspired oxygen
Rats are anesthetized using isofluorane gas delivered in a balance of oxygen. Chang-
ing the carrier gas to medical grade air, consisting of 21% oxygen in nitrogen, allows
the tissue to return to ambient oxygenation. A single device was implanted in a
rat gastrocnemius muscle, and measurements were made twelve days later. Oxygen
was maintained for one hour before switching to air. The gas was changed back to
oxygen 30 min later. The transition from oxygen to air caused an increase in T 1; no
change was observed in the transition back to oxygen. Other researchers have noted
that the recovery is both slower and less pronounced [78]. It is likely that a longer
wait time at each level is needed.
4.5.2 Restriction of circulation
An oxygen sensor was implanted in the calf muscle of an anesthetized Sprague-
Dawley rat using a biopsy needle. The sensor was monitored for two hours. The
relaxation time increased over the course of the measurement, consistent with a de-
creasing oxygen concentration inside the sensor chamber. The sensor was initially
in ambient air and then implanted into muscle, which has a lower oxygen concen-
traion. The sensor T is expected to increase immediately after implantation as the
oxygen diffuses out of the sensor. Approximately one hour was needed to equilibrate
with the tissue. There is evidence that some of the liquid phase siloxane (DDMPS)
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Figure 4-3: Boxplot of T1 measured by a sensor implanted in a rat calf muscle. The
inspired gas was changed from oxygen to air, and an increase in T followed. A
second transition back to oxygen did not show a corresponding difference. A longer
time might be needed for the recovery.
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diffused into the muscle tissue. The equilibrium signal amplitude, So, decreased by
30% two hours after implantation.
A measurement eight days after implantation included a flow restriction to the leg.
The animal was kept under anesthesia for over an hour to ensure that the muscle
and sensor were fully oxygenated. A nylon cuff, lightly tightened around the thigh,
reduced the blood flow to the limb. An increase in the relaxation time was observed
after the restriction (p < 0.01), consistent with a lower oxygen tension in the muscle
tissue. The data are shown in Figure 4-4.
4.6 Prospects
Tissue oxygen tension is an important parameter not only for cancer but also for heart
disease, traumatic injury, and compartment syndrome. The experiments shown in
this chapter demonstrate a method for wirelessly measuring tissue oxygenation. The
siloxane is not a contrast agent but has a very high oxygen solubility and a long
inherent T 1. The oxygen that diffuses into the siloxane significantly impacts the
measured T as predicted by the theoretical model. The silicone is hydrophobic and
fully dense; it will exclude water, proteins, and immune cells when implanted in the
body. The other gases that can diffuse into the polymer, such as nitrogen and carbon
dioxide, are not paramagnetic and will not influence the measurement. The sensor
will only measure oxygen inside the body.
Some of the liquid siloxane may be escaping from the matrix into the muscle tissue.
Other siloxanes should be explored that covalently bond the long chains to a back-
bone molecule. Covalently bonded molecules cannot escape from the sensor chamber,
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Figure 4-4: T measured in a calf muscle under free and constricted circulation. A
significant increase in relaxation time is observed after applying light pressure to the
thigh.
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and the sensor will be stable indefinitely. The covalent bonding, however, is likely
to reduce the transverse relaxation time, T2, and the overall sensitivity will suffer.
The sensitivity metric of Equation (4.10) can be used to select the best candidate
material.Alternatively, a uniform-field magnet could provide sufficient signal to dif-
ferentiate between the matrix and liquid components to compensate for any change
in the blend ratio.
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Chapter 5
pH sensing
Measuring pH in the body can serve as a general and non-specific indicator of tissue
health. Damaged cells release their acidic contents into the surrounding environment.
Solid tumors are known to be acidic compared to normal tissue because cancer cells
undergo anaerobic respiration, producing lactic acid as a by product [79]. Tumors
induce the formation of blood vessels to provide oxygen and nutrients, but these
vessels form in a haphazard arrangement that leaves some regions poorly perfused.
Cancer cells begin to die in those regions, which become necrotic and more acidic [11].
Chemotherapy, when effective, initiates the cells' self-destruct mechanism (apopto-
sis), and the acidic contents of the cell are released into the extracellular space. The
tumor environment is usually pH 6.5 and becomes more acidic, around pH 5.5, when
the treatment is successful [70]. None of the local pH changes in the tissue would
manifest themselves in systemic measurements of pH; the body has multiple buffering
mechanisms to maintain very strict control over the pH. Tissue pH must, therefore,
be measured at the site of interest.
127
5.1 Electrochemical pH sensors
Electrochemical probes are the gold standard for measuring pH, and certain models
are built into a hypodermic needle for tissue measurement. Direct tissue measure-
ments are possible, but these probes cannot be left behind for repeat measurements.
Each measurement is invasive and requires anesthesia and image guidance. Plus,
the heterogeneous makeup of tumor cells and vessels results in regions of higher and
lower pH. Repeat measurements that seek to track therapy are unlikely to measure
the same location twice. Instead of measuring a trend over time, they would deter-
mine the range of pH across space. An implanted sensor will monitor a single location
over time. It is the preferred approach for detecting changes in pH in response to
treatment because it will eliminate variations due to placement.
Electrochemical sensors are extremely fast and accurate if calibrated against known
pH buffers. A voltage, measured across two electrodes, is converted to a pH by
calibrating against known buffers. Long term or repeat monitoring is possible, but
periodic recalibration is required. The electrodes are prone to contamination and
are incompatible with certain ion species. The possibility of implanting the pH
electrode in the body permanently presents many insurmountable challenges. One
study implanted a small vessel with an electrode solution directly into a tumor.
This created a clean chamber into which a needle probe was inserted to measure
the pH. This arrangement enabled the repeat sampling of the same point in the
tumor and eliminated the possibility of contamination, but it still required multiple
invasive procedures for the patient. The researchers demonstrated that the tumor
pH decreases when the chemotherapeutic is successful and highlighted the benefits
of tracking intratumoral pH in the clinic. Their approach may not translate into the
128
clinic; as the authors themselves noted, "a modified system of measurement would be
required for routine clinical application [. . . ] The obvious problem with this approach
is the innate, potential discomfort for patients" [70].
The wireless implantable sensor presented in this thesis overcomes these limitations
while still measuring the same location. Implanted during the biopsy procedure,
the sensor is no more invasive for the patient than existing practice. Repeat mea-
surements are completely non-invasive. The work in this chapter was performed in
collaboration with Vincent Liu.
5.2 HEMA-BIS gels for pH measurements
The sensing medium consists of hydroxethyl methacrylate (HEMA), which has a
long history of use in contact lenses [80]. The gel is formed by crosslinking HEMA
with bismethacrylate (BIS). The reaction is a simple free-radical polymerization that
occurs in an oxygen-free environment and that is completed in several hours at room
temperature. The wireless sensors can be filled directly with the prepolymerized
mixture, and the reaction proceeds inside the chamber.
The gel is a weak acid with an acid dissociation constant pKa. Protons on the gel
can be exchanged with protons on the surrounding water molecules, and the rate of
exchange is pH-dependent [?]. The NMR relaxation of protons on the polymer is
very fast compared to the relaxation in water. The combination of pH dependent
exchange with differing relaxation rates gives rise to pH-dependent NMR contrast.
Acidic conditions with pH values below the pKa result in more protons associated
with the polymer chain. The resulting T2 is shorter because the fraction of faster
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relaxing protons is greater. Basic conditions, pH > pKa, fully dissociate the acid,
and the polymer has a smaller impact on the overall relaxation.
The gel is a weak acid, and its buffering ability must be fully overcome to measure
the T 2 versus pH calibration curve. A small amount of gel is tested in a large bath
of pH-adjusted fluid; the large volume excess of the bath over the sensor ensures
that the bath pH will not be affected by changes inside the gel. The gel is loaded
into a sensor, which confines the measurement to the gel, and no signal is detected
from the fluid bath. The sensor was mounted inside a 6 mm diameter plastic tube
and centered inside the reader coil. Approximately 500 mL of saline solution was
maintained at 37 C in a circulating water bath. The solution pH was adjusted with
concentrated hydrochloric acid or soduium hydroxide and measured with a pH meter
(Omega). Continuous flow over the sensor was maintained with a peristaltic pump
(Masterflex).
Data acquired over a period of approximately 25 days are shown in Figure 5-1. The
saline pH was adjusted in discrete steps between pH 4.8 and pH 7.5. The sensor
responds reversibly and equilibrates in approximately 24 hours. The equilibrium
T2 versus pH data are shown in figure 5-2. The T2 is shortest at low pH, which
is consistent with more coordination of the protons on the polymer chain. The T2
increases with increasing pH, as expected, but drops above pH 6.8. This drop is
likely due to a second exchange mechanism becoming active. There are multiple
exchangeable protons along the polymer chain, each with a potentially different dis-
sociation constant [81]. Each site may also differ in its chemical shift such that a
high-field spectrometer could distinguish each individual site. A sensor measured
with a single-sided magnet cannot observe chemical shift. and only the aggregate re-
laxation is detected. Tumor pH, however, will mostly be restricted to the left portion
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Figure 5-1: Measurements of T 2 versus pH of a saline solution using HEMA-BIS
gel inside a sensor. A peristaltic pump maintained a constant flow of saline from
a temperature controlled bath over the device. A pH probe in the bath monitored
both temperature and pH.
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of the curve, and it is the low-pH regime that is of interest.
The monotonic portion can be modeled as a weak acid with a dissociation value
pKa. The model assumes that there are two distinct relaxation rates; relaxation is
fast on the polymer chain and slow in free water. The pH versus T2 data are fit to
the following form:
1 1 11- =1 + (5-1)
T2  T2,0  T2,(1+ 10pH-pK)
where T2,0 and T2,b represent relaxation parameters to be found. More basic con-
ditions, pH > pKa, result in T2- > T2,o, whereas acidic conditions pH < pKa
eliminate the exponent, and 1/T 2 = 1/T 2 ,0 + 1/T2,b.
The gel would need to be modified to measure healthy tissue because normal pH is
outside the monotonic regime; the acidic pH of a tumor, however, is within the sen-
sitive range. The sensitivity in this regime can be explored using the measurements
that generated the calibration curve. The predicted pH from each T2 measurement
is compared to the pH of the saline bath. Figure 5-3 shows a histogram of the differ-
ence between predicted and actual pH values from 1,010 measurements. The limit
of detection is better than 0.1 pH units across the monotonic regime.
5.3 Temperature dependence
The temperature of the saline bath was changed between room temperature and
approximately 50 C. The measured relaxation time decreases with increasing tem-
perature. The data are plotted in Figure 5-4 for three different values of the solution
pH. The temperature range expected in the body will not vary by more than a few
degrees Celsius. The temperature-induced change in T2 is unlikely to significantly
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Figure 5-2: T 2 versus pH calibration curve.
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Figure 5-3: Histogram of pH measurement error establishing a limit of detection
better than 0.1 pH units.
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impact the measurement, but the calibration curves should be acquired close to body
temperature.
70-
60- pH 7.1
50-
pH 6.0
40-
30 - pH 5.2
20
20 30 40 50
Temperature ("C)
Figure 5-4: The measured T2 decreases with temperature. The expected temperature
deviation in vivo is very narrow compared to the studied range, but the calibration
curve must be performed at body temperature.
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Parameter Value Description
Nscans 16 number of averaged scans
TR 1250 ms repetition time
TE 50 ps echo time
Nechoes 3000 number of echoes
Att9o -18.5 dB pulse attenuation
too 2.5 ps pulse duration
Nsamples 32 samples per echo
dt 0.5 ps dwell time per sample
Table 5.1: Acquisition parameters for measuring the transverse relaxation time, T 2.
5.4 Pilot study
Four C57-BL6 breed mice were inoculated subcutaneously with melanoma cells de-
rived from the same breed. Sensors were implanted after one week using a biopsy
needle. One was implanted directly inside the tumor, a second was implanted ad-
jacent to the tumor and a third was implanted on the contralateral side. A fourth
animal had no sensor implanted to ensure that the signal was indeed from the sen-
sor and not from the surrounding tissue. The animals received daily injections of
doxorubicin into the peritoneal cavity and the sensors were measured. No signal
could be detected from the mouse that did not have an implanted sensor, confirming
that the signal is from inside the sensor and not a measurement of the tumor by the
reader coil.
Each relaxation measurement took approximately four minutes with the acquisition
parameters listed in Table 5.1. Multiple measurements were acquired and averaged
during post-processing. The echo amplitudes were estimated using the least-squares
method outlined in Appendix A.
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Figure 5-5: Relaxation time measurement for sensors implanted inside, near, and
contralaterally to the tumor. The sensors on the tumor side measured a shorter T2 ,
consistent with a lower tissue pH.
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The results from the three implanted sensors are shown in Figure 5-5. The sensor
on the contralateral side shows a sustained high T2 over the course of 6 days. The
sensor implanted adjacent to the tumor shows a lower T2 for the first few days but
the lowest pH is recorded in the sensor implanted inside the tumor. This experiment
demonstrated in vivo operation of the implantable NMR probes. The difference
between the tumor-side and contralateral implantation are in agreement with the
expected pH of cancerous tissue versus normal tissue.
5.5 Detecting chemotherapeutic efficacy
Determining chemotherapeutic efficacy represents a challenging problem in the clinic
but one that can have profound impact on the course of cancer therapy. The difficulty
in a research model is to separate the morphological changes in a growing tumor from
the immediate effect of the treatment. If the tumor proliferates rapidly, some regions
may become starved of nutrients and become necrotic. Necrosis is different than
apoptosis, which is the cells' controlled self-destruct mechanism, that can be induced
by chemotherapy. The pH change is a general indicator of cell death regardless of
the origin.
A pilot study between treated and untreated animals suggests that 95% significance
would be achieved with six mice per group. Twelve mice were inoculated with the
melanoma cells. Sensors were implanted inside the tumors approximately ten days
later. The mice were randomly assigned to a treatment group (N=6) or a control
group (N=5). The treatment group received daily intraperitoneal injections of dox-
orubicin. The dose was proportional to the mass of the mouse (0.02 mg/g). The
control group received a saline injection of similar volume. The mice were monitored
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carefully for any signs of distress, and the experiment continued for four days.
The sensors were measured daily after each injection. The results show no separa-
tion between the two groups (Figure 5-6). The spread in T 2 measured on Day 1 is
expected because tumors are heterogeneous and each sensor measures a slightly dif-
ferent environment. Because the initial pH may vary depending on location, it may
be better to look at changes in pH over time rather than an absolute pH. However,
there is still no discernible difference between the treated and untreated mice.
It is useful to investigate the normal range of pH (or relaxation time) in untreated
tumors. The pH will depend on the exact location of the sensor inside the tumor.
All of the measurements on Day 1 were prior to treatment and are included in the
analysis. Figure 5-7 shows a slow decrease in the mean T2 at a rate of approximately
1.5ms/day. The slope is negative with 95% confidence indicating that the tumors
are becoming more acidic as they grow. The majority of measurements are between
55 ms and 65 ms corresponding to pH 6.5 and higher. The lowest pH measured using
the implanted sensor was approximately pH 6.
A tumor growth study without an implanted sensor showed significant tumor cell
death even in the untreated mice. One histologic section stained with hematoxylin
and eosin (H&E stain) is shown in Figure 5-8. The dark brown spots are melanin
and are characteristic in melanoma. The H&E stains cell nuclei blue/purple while
the cytoplasm and other proteins are pink. Significant regions without cell nuclei are
necrotic and contain no living cells. Apoptosis, caused by the chemotherapy, would
be visible inside the regions with living, well-perfused melanoma cells. The extent
of tumor necrosis is apparent in a side-by-side comparison of treated and untreated
tumors (Figure 5-9). The similar staining pattern suggests that the drug dose was
not sufficient to cause a significant change in the tumor compared to its natural
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Figure 5-6: Measured relaxation times for sensors implanted in mouse tumors. Those
animal receiving treatment (doxorubicin) are shown as solid red lines, and the control
group that received saline injections are shown in dashed black lines. Each line
represents a different animal. No discernible pattern emerges between the two groups
suggesting that this dose had no effect on the tumor pH.
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Figure 5-7: Measured relaxation times for implanted sensors that received no treat-
ment. The mean T 2 (thick red) decreases over the four days of implantation consistent
with a net trend towards more acidic conditions in the tumors.
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Figure 5-8: Histologic section of an untreated tumor (H&E stain). Significant regions
of necrotic tissue are mostly stained pink. Healthy melanoma cells have purple-
stained nuclei. The brown spots are melanin, characteristic of melanoma.
progression. A higher dose is likely necessary to ensure that chemotherapy-induced
apoptosis, and not necrosis, is the predominant cause of decreasing pH.
5.6 Conclusion and future work
The implantable probe loaded with HEMA-BIS gel was shown to detect pH accu-
rately in pH adjusted saline over the range of pH expected inside a tumor. The
sensors are reversible, equilibrate in 24 h, and are stable for almost a month.
Implanted inside tumors in a mouse melanoma model, the sensors were unable to
distinguish between treated and untreated mice. Histological analysis found similar
patterns of necrosis in both groups suggesting that there was no underlying dif-
ference for the sensors to detect. It is, indeed, possible that the sensors correctly
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Figure 5-9: H&E stained sections of treated and untreated tumors. Substantial
regions of necrotic tissue (pink with no purple stained nuclei) are apparent in both
sections.
demonstrated that the drug was not effective.
Histology also revealed an increase in the amount of necrotic tissue over time; this
is consistent with gradual decrease in T2 over the course of the measurement. The
spread in relaxation time measured across animals is expected. The pH will vary
depending on where inside the tumor the measurement is made. Implanted sensors
have a significant advantage over needle probes because they measure the same spot
repeatedly.
This study does not definitely prove pH as a marker for detecting treatment efficacy.
Future studies should establish a treatment regimen that produces a profound tumor
change. The protocol will require a higher doxorubicin dose to ensure tumor cell
death. If possible, the sensors should be implanted in smaller tumors, which have
less necrotic tissue, to reduce the effect of necrosis on the pH change. A doxorubicin
resistant cell line derived from the same melanoma model will provide the control
experiment.
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Chapter 6
Detecting protein biomarkers
Soluble proteins, measured in blood, can serve as markers of biological activity.
Blood tests can indicate the onset of a myocardial infarction (heart attack), predict
some types of cancer, and report on the function of several organs. Detecting these
biomarkers with an implanted device could serve as an early warning system or
provide feedback on the progress of treatment.
Magnetic nanoparticles with a polysaccaride coating are used as contrast agents in
NMR [82]. Antibodies conjugated to the particles form a protein-dependent con-
trast agent. The functionalized particles aggregate around the protein of interest
and change the transverse relaxation rate of the solution. The resulting T2 can be
correlated to the amount of bound protein [83].
One example protein is human chorionic gonadotropin (hCG) that is produced by
choriocarcinoma. Particles functionalized with anti-hCG antibodies were encapsu-
lated in a device using a semipermeable membrane. The device is shown in Fig-
ure 6-1. The membrane has pores that are smaller than the particles but larger than
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the protein; it traps the particles while allowing the protein to diffuse freely into
the chamber. The relaxation time was measured using magnetic resonance imaging
(MRI). Devices implanted in a mouse cancer model demonstrated detection of the
cancer marker [84].
semipermeable membrane
adhesive
plastic body
Figure 6-1: Prototype device used to test protein detection. Sensitive nanoparticles
are encapsulated in a plastic body using a semipermeable membrane that keeps the
nanoparticles in but allows the target to pass.
Ling et al. developed a multiplexing technique that uses a single class of particles
functionalized with secondary antibodies against mouse antibodies. Any mouse-
derived primary antibody can be added to these particles to form a vast array of
protein-sensitive contrast agents [85]. Multiple reservoirs can be built on a single
device to detect a panel of protein biomarkers [86].
Cancer biomarkers are an area of active research, but their utility has proven con-
troversial. Elevated levels of prostate specific antigen (PSA) were thought to be pre-
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dictive of prostate cancer, but recent work has cast doubt on that conclusion. The
original analysis was confounded by the very high prevalence of enlarged prostate,
and PSA levels are far less predictive of prostate cancer. The absolute blood PSA
concentration that triggers further tests has increased the number of unnecessary
biopsy and surgical procedures [87, 88]. Should cancer biomarkers be discovered
that are diagnostic or predictive, then nanoparticle-based agents can quickly be cre-
ated to detect them. The sensing technology is instead tested in a different model
for which the diagnostic concentrations are known.
6.1 Cardiac biomarkers
Cardiac markers follow a very well known profile following cardiac tissue damage.
A panel of proteins can determine whether heart tissue damage has occurred within
the past 72 hours. The myocardial infarction model was chosen as a better proxy for
testing protein sensors.
Disc sensors (Figure 6-1) were filled with nanoparticles functionalized with antibod-
ies against a standard cardiac panel: myoglobin, troponin I, and creatine kinase MB
(CKMB). The sensors were tested in saline solution spiked with varying concentra-
tions of the three proteins and in a mouse model of myocardial infarction.
Research presented in this section was performed in collaboration with Yibo Ling
and Terrence Pong [89, 90].
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6.1.1 Exposure
The antibody-protein interaction is generally irreversible, and so the sensors will
continuously collect the protein. The measurements contain the history of the con-
centration profile. Integrating the concentration, C(t), as a function of time yields
an exposure. The exposure measurement reflects the total amount the device has
been exposed to up until that point in time. This is formally defined as
E(T) j C(t)dT. (6.1)
Ten identical myoglobin sensors were exposed to different concentration-time pro-
files. They were measured continuously over a period of several days. The sensor
response to constant concentrations is shown in Figure 6-3. The sensors show a
continuously increasing T2 over time. The rate of increase of T2 depends on con-
centration, but the final value is the same for all conditions, suggesting that the
antibodies are fully saturated. Plotting T2 versus exposure collapses the curves onto
a single, characteristic T2-exposure profile. Furthermore, the sensors exposed to
transient concentration profiles also lie along the T2-exposure curve (Figure 6-4).
6.1.2 Mouse myocardial infarction model
The dosimeter property was exploited in a mouse myocardial infarction (MI) model.
The left anterior descending artery was ligated with a suture to cause downstream
tissue damaged. A sham procedure involved all of the steps except the ligation, and a
control group received no procedures. Sensors were implanted subcutaneously in all
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Figure 6-2: Antibody based sensors measure exposure, defined as the time integral
of concentration. Transient events can be detected because exposure remains high
even after the concentration has subsided.
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Figure 6-3: Measured T2 versus time. Sensors exposed to steady concentrations of
myoglobin respond at different rates but saturate to the same value. Adapted from
Ling, Pong, Vassiliou et al. [89].
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Figure 6-4: Measured T2 versus myoglobin exposure. The measurements from Fig-
ure 6-3 all lie along a characteristic T2 vs exposure curve. Transient profiles (markers)
simulate one-off events and also lie along the curve. Adapted from Ling, Pong, Vas-
siliou et al. [89].
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of the animals and were explanted the following day for measurement. The sensors
distinguished the MI group from the other two groups. Furthermore, the change
in relaxation time correlated with the amount of tissue damage as determined by
histology of the heart tissue [89]. A single concentration measurement in blood does
not give any information on how much tissue was damaged. This study demonstrated
that protein biomarkers can be detected with subcutaneously implanted sensors; the
sensors do not need to be implanted near the heart. It suggests that other soluble
proteins detected with a blood test are also possible targets for a subcutaneous sensor.
6.1.3 Future cardiac sensor applications
The study points to a clear application for monitoring patients at risk for a heart
attack. A small sensor implanted under the skin could be tested daily, at home, or
during routine visits to the doctor's office. Detecting silent MIs, those that are not
felt by the patient, would ensure that the patient received prompt care and followup
treatment in advance of a more serious cardiac event.
A patient undergoing chemotherapy is at risk for cardiotoxicity; the heart muscle is
damaged by the cancer drug. A subcutaneously implanted sensor could monitor the
patient's heart over the course of treatment. Just as an X-ray dosimeter signals that
a maximum allowable exposure has been reached, the sensor would indicate when
the patient is in danger of severe cardiac toxicity.
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Figure 6-5: Sensors implanted in a myocardial infarction (MI) model. MRI mea-
surements of the sensor (a) show one possible use. Sham and control experiments
show that the sensors indeed detect the MI (b). The measured T2 increase with the
amount of damaged tissue (c-e) as would be expected from Figure 6-4. Reproduced
from Ling, Pong, Vassiliou et al. [89].
153
a
b
S
I-
4
14
12-
10.
8.
6-
4-
2
0
cTnl
6.2 Nanoparticle aggregation
Magnetic particles have long been known to increase the relaxation rate in fluids, and
established models exist for the mechanism behind this contrast [39, 91, 92, 93, 94].
The theory developed to calculate relaxation due to single spherical particles was
applied to clusters of particles [95, 96, 97]. The particles are assumed to bind under
diffusion-limited aggregation to form fractal structures. The single-particle theory
is applied by modeling a new sphere with reduced magnetization per unit volume.
The simultaneous assumption of a fractal aggregate and a solid sphere appears to
be contradictory. The model, however, predicts the correct qualitative change in
T2 as the particles aggregate. The scaling of T2 with aggregation was simulated
in collaboration with Keith Brown and published in the Journal of Magnetism and
Magnetic Materials [98]. Numerical simulations of the random-walk diffusion of
water molecules around magnetic particles confirmed the results of the simplified
solid sphere model.
A second simulation considered the following thought experiment: form a chain of
magnetic particles and rotate the chain relative to the field while measuring T2. The
single-particle model would predict a constant T2 regardless of the chain's orientation
with respect to the field because it has no orientation-dependent parameters. The
simulation, however, revealed that T2 has an angular dependence. The relaxation
time is at a minimum when the chain is perpendicular to the magnetic field.
The experimental verification of this model was performed in collaboration with
Melanie Adams as part of the MIT Undergraduate Research Opportunities Program
(UROP). Magnetic particles of diameter 1 m (Dynabeads MyOne, Invitrogen Dynal
AS, Oslo, Norway) were chosen for their very narrow size distribution, which is
154
revealed in the scanning electron micrograph in Figure 6-6. These particles consist
of iron oxide nanoparticles in a polystyrene matrix [99].
10 Pm 2 jim
Figure 6-6: Scanning electron micrograph of 1 jim beads.
The particles were suspended in molten solution of agarose (Sigma-Aldrich) and
transferred to a 5 mm NMR tube. Multiple tubes were filled with the particle sus-
pension. The tubes were placed inside an electromagnet with a field of strength
of 4 mT. A water-cooled heatsink gelled the agar solution, while the sample was
inside the magnetic field, to trap the particles. Incubation times varied from 0 min
to 30 min to form chains of different lengths. The aggregation is shown schemati-
cally in Figure 6-7. Micrographs of the chained and dispersed particles are shown in
Figure 6-8. Analysis of multiple photographs of the chained particles yielded a power-
law relationship between chain length and incubation time, as shown in Figure 6-9.
The relaxation time, T 2, was measured using a benchtop relaxometer (Minispec mq-
20, Bruker Optics) using a standard CPMG pulse sequence. The angle between the
chain axis, B, and the NMR field, B0 , is defined as 0c and is shown in Figure 6-10.
A geared sample holder rotated the tube at a rate of 3.75 turns per hour using an
off-the-shelf quartz clock movement. The T2 was measured continuously over several
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Be=z 4 mT
Figure 6-7: A tube containing particles suspended in molten agarose is inserted into
a weak magnetic field. The particles begin to form chains. A water-cooled jacket gels
the agar solution after a predetermined time, and the particle formation is captured.
Figure 6-8: Bright field transmission micrograph of 1 pm beads suspended in
agar. The chains were created by magnetizing the sample using an electromagnet
(B=4 mT).
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Figure 6-9: The average chain length determined by optical imaging shows a power-
law increase with time inside the 4 mT magnetic field.
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,BC
Figure 6-10: The tube is rotated along an axis perpendicular to instrument field, BO,
with 0, being the angle between particle chains and BO.
complete revolutions of the sample. A representative data set reveals the sinusoidal
variation of relaxation time as a function of angle (Figure 6-11), as predicted by
the Monte Carlo simulations. The data are fit to a cosine function to give a mean
relaxation time, T2, and a swing in relaxation time AT 2 .
The mean T2 shows an increase as expected for large particles [94, 101, 97]. The
difference between the maximum and minimum T2 also increases with chain length
and appears to follow a power law. The AT 2 versus time has the same exponent as
the mean chain length suggesting that it may be a better measure of chain length
than the mean T2.
The experiments and simulations demonstrate clearly that chains of particles cannot
be modeled under the assumption that they are simply large spherical particles. This
picture is neither valid nor intuitive satisfying. Finite element analysis of the field
pertubation caused by a chain of three particles is shown for three different orien-
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Figure 6-11: Relaxation time measurements as a function of angle between the mag-
netized direction, B, and the measurement field direction, BO.
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Figure 6-12: Measured relaxation time as a function of magnetization time shows a
power law increase of T2 with time.
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Figure 6-13: The difference between high and low T2 values as the sample is rotated
relative to the magnetic field also increases as a function of magnetization time and
chain length.
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tations in Figure 6-14. Similar analysis on single beads and two- and three-bead
B
9c=0 Oe=45 9c=90
Figure 6-14: Isosurfaces of field perturbations caused by a three-particle chain at
different angles to the field. The top and bottom surfaces (red) bound the 1%
positive field deviation, and the center, torroidal surface (blue) bounds the negative
1% field deviation. The shape and volume of the 1% boundaries change with angle
and are responsible for the angular dependence of T2 .
chains revealed an angular dependence on the volume of the magnetic field pertuba-
tion. Figure 6-15 shows how the perturbed volume fraction varies as a function of
angle. A single particle shows no angular dependence as is expected, but is included
to ensure the finite element model is sufficiently well meshed. Aligned chains (Oc = 0)
generate a larger volume, indicating an overall gentler field gradient. The CPMG se-
quence can compensate for lower gradients more efficiently and measures a longer T2 .
Chains rotated away from the field axis create a stronger field perturbation, and the
1% boundary encloses a smaller volume. The volume is not a predictor of relaxation
time but hints at the root cause of how relaxation changes with particle orientation.
It is the time-changing field that the water molecules experience that determines the
relaxation time [102]. Spherical particles offer a simplification because the field per-
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Figure 6-15: The volume of solution for which the field is perturbed at least 1% is
shown versus chain angle and normalized to the particle volume. The three-particle
chains show a gentler field gradient consistent with an increasing T2. Rotating the
chain 900 increases the field gradient, and a shorter T 2 is expected.
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turbation and the characteristic length are both defined by the radius. The effective
radius for a chain is some combination of the chain length for water diffusing along
the chain and the particle radius for orbital motion. Random-walk simulations of
diffusing water molecules can estimate T2 directly, but it is instructive to look at the
field perturbations caused by the particular particle orientation.
6.3 Prospects
Implanted sensors can detect soluble biomarkers. Proteins were the main focus of this
chapter, but other targets can be detected by choosing the appropriate ligand for the
particle surface. Magnetic particles have been developed for detecting peptides [103,
104] and short strands of nucleic acids [105].
The sensors continuously capture the target, and a single measurement reports the
total exposure. This historical information can be more clinically relevant than
single-point concentration measurements as shown for cardiac muscle injury.
Cardiotoxicity is a serious concern for patients undergoing chemotherapy. An im-
planted sensor could monitor the patient to warn when dangerous levels have been
administered. The implantation would be for a relatively short period and only
a very small amount of contrast agent is needed. The quantity of contrast agent
inside a sensor is approximately 10-6 the amount that would need to be injected sys-
temically. The encapsulation of this tiny amount virtually eliminates any potential
for toxicity or an immune response. A cardiotoxicity sensor for monitoring cancer
patients should face an easier path towards regulatory approval owing to its short
residence time, low risk of toxicitiy, and dire medical need.
164
Chapter 7
Conclusion
This thesis presents a new device for direct sensing in living tissue. Emphasis was
placed on monitoring cancer from within the tumor and providing the oncologist
with information that is not available by other means. The sensor was designed to
be deployed during a biopsy procedure and to report back on the state of the tumor
environment. Because tumors are both hypoxic and acidic, and yet no easy method
exists to measure those quantities, the sensor was designed to provide those data.
Miniaturization and wireless detection were achieved through a new approach to
nuclear magnetic resonance (NMR) that builds a small portion of the instrumentation
on the implant. Sensors for oxygen, pH, and soluble proteins were developed by
incorporating appropriate NMR contrast agents.
A new approach to spatial localization in NMR was explored in Chapter 3. It elim-
inates the need for magnetic resonance imaging (MRI) to measure the sensor. MRI
produces a full picture inside the body. If a contrast agent is embedded in the tissue,
it can be located and measured using MRI. The data are processed to extract the
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required information, which is one number that represents a chemical concentration;
the rest of the image is discarded. The sensor's on-board circuit acquires the nec-
essary information by only measuring the contrast agent; this approach is simpler,
more direct, and does not waste costly MRI time for a non-imaging purpose. The
sensor and a reader probe, which sits outside the body, are two resonators coupled
through their mutual inductance. The reader's weak oscillating excites the sensor,
and there is a 40-fold field gain inside the sensor chamber. This enhancement ensures
that only the sensor's contents are involved in the NMR experiment and the rest of
the tissue is ignored. While the MRI acquires data on the entire region and then
extracts the parameter of interest, the sensor directly reads that one parameter.
The instrument's specific sensing capabilities are provided by contrast agents inside
the sensor chamber. Oxygen was detected in a silicone material. A pH sensitive
polymer measured tumor acidity. Antibodies attached to nanoparticles created a
protein sensor.
The oxygen sensor, presented in Chapter 4, is intended for the study of tissue hy-
poxia. Hypoxia is implicated as a driving force for metastasis, it inhibits the action
of chemotherapy and radiotherapy, and it is being investigated as a possible target
for treating cancer [9, 69, 70]. An implanted sensor can study all of these effects in
a research setting and monitor patients undergoing treatment or enrolled in clinical
trials. The sensor contains a silicone matrix embedded with a liquid siloxane. The
material has a very high oxygen solubility, and it is the paramagnetism of molecu-
lar oxygen that provides the constrast. The ability to track oxygen inside a tumor
allows researchers to ask new questions: "How important is tumor hypoxia on ra-
diation and chemotherapy dose?", "Does inspiring pure oxygen help treatment?",
"Do antiangiogenic factors reduce the oxygen supply to a tumor?" Answering these
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questions could provide new guidance on how an oncologist should treat a patient
and reveal new targets for therapies. For example, an oxygen sensor in a clinical trial
could preselect patients for hypoxia. The hypoxia-activated drug, tirapazamine, may
prove successful if tested in patients with confirmed hypoxia. One can envision oxy-
gen sensors being used routinely during clinical trials to reveal whether preselecting
for hypoxia is necessary. Clinical drug trials are risky and expensive; the small incre-
mental cost of adding a tumor oxygen sensor would more than pay off if it identifies
a subpopulation that benefits from the drug.
Tumors are acidic, and prior work has suggested that when a potent chemothera-
peutic is administered they become more acidic [11, 44]. The benchtop testing of a
pH sensor in Chapter 5 showed it to be fast, accurate, and stable. The melanoma
study did not achieve the therapeutic effect, and histology showed no difference be-
tween treated and untreated tumors. There was no drug effect for the sensors to
measure, but there was evidence of a gradual decrease in pH over the course of the
experiment. This was consistent with the increasing necrosis shown by tissue his-
tology. Future experiments should establish a new dosing regimen that produces a
response to chemotherapy and should histologically verify that response. The exper-
iment can be repeated with an implanted sensor to explore pH change as an indicator
of treatment. The most important consideration when monitoring tumor pH is the
wildly heterogeneous makeup of the tumor: the pH will vary from point to point
throughout the tumor. Because an implanted sensor measures the same location
repeatedly, it tracks the temporal change in pH rather than the spatial variation. It
should therefore prove an excellent indicator of treatment efficacy in response to a
chemotherapeutic.
Soluble proteins released from damaged heart muscle cells enter circulation and can
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be detected anywhere in the body. This may suggest that a blood test is sufficient to
detect cardiac damage and that an implanted sensor is not necessary at all. Chap-
ter 6, however, showed that a protein sensor is useful becuase it measures the sensor's
total exposure to the protein rather than an instantaneous concentration. Exposure
represents the entire history of a protein's concentration in the body and is a more
clinically relevant metric in some instances. Sensors measuring a cardiac panel in a
myocardial infarction model demonstrated that protein exposure correlated with the
amount of damaged heart tissue. Where a blood test simply identifies that damage
has occurred, the sensor can quantify the amount of tissue damage.
The protein sensor's ability to measure total cardiac damage has a direct applica-
tion in monitoring cardiac toxicity induced by chemotherapy. An oncologist could
quantitatively monitor the extent of cardiac toxicity and take action before a critical
level is reached.
The implanted sensor presented in this thesis was designed to fit through a biopsy
needle because almost all cancer patients will undergo a tumor biopsy. The sensor
can be implanted without any additional discomfort to the patient and is effectively
non-invasive. It has the potential to predict therapeutic outcome and guide treatment
options. Most importantly, through its direct access to the tumor, the sensor will give
the oncologist rapid feedback and save valuable time in the early stages of treatment.
The patient will be started on the right drug sooner and spared the unnecessary side
effects of ineffective treatment.
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Future work
The implantable sensor is a powerful preclinical research tool. It offers direct, repeat,
and non-invasive measurements on tissue. Researchers can incorporate the sensor
into their own preclinical models and track the same animal over time. The sensor's
report of tissue oxygen or pH offers a general, non-specific indicator of tissue health.
Oftentimes a marker that is specific to a tissue or a condition must be tracked, and
the sensor can exploit any of a variety of NMR contrast mechanisms to measure
those markers.
A natural extension of this work is to create a system that does not require advanced
knowledge on the part of the end user. The work in Chapter 3 offers the critical
elements: a set of identical sensors, a reader coil that is insensitive to the position
of the sensor, and a method to pre-tune the system. The missing component is a
uniform field magnet that would allow a mouse to be inserted into the reader and
the measurement to proceed automatically. The mice could be trained to enter the
magnet willingly, eliminating the need for anesthesia and allowing more frequent
measurements.
The pH and oxygen sensors were demonstrated separately but could be combined into
a single sensor. Figure 7-1 shows the concept of a double sensor. The siloxane would
first be cured as a ring leaving space in which the pH-sensitive gel can be polymerized.
The two materials have significantly different relaxation time constants, and so they
can both be measured simultaneously. The result is a combined sensor for measuring
tumor hypoxia and pH.
NMR spectroscopy distinguishes specific chemical groups and identifies many molecules
by their NMR spectrum. Adding spectroscopic ability to the sensor's enhanced
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pH sensing gel
oxygen sensing polymer
Figure 7-1: Concept implantable sensor for simultaneous pH and oxygen measure-
ments.
signal-to-noise ratio could open up a wide array of chemicals that can be detected
in vivo. A uniform magnetic field is absolutely necessary, and shim coils must be
added to eliminate small field imperfections. The sensor would not need to change
physically, but the materials would need to be chosen to avoid any permeability mis-
match that would distort the magnetic field. The sensor chamber is a very clean
environment in which to perform spectroscopy, especially compared to tissue. The
sensor chamber could be filled with a polymer matrix that excludes cells and large
molecules. The sensor could then search for small molecules based on their NMR
spectrum or based on their interaction with specific side groups on the polymer
matrix. The system will never achieve the level of sensitivity of a high-field NMR
spectrometer, but the basic spectroscopic techniques would open up a vast array of
possibilities for in vivo sensing, such as small molecules, markers of metabolism, and
neurotransmitters.
A hand-held or even wearable system is possible considering the low power require-
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ments of the measurement. Because the reader creates a weak field, only a lower
power pulse amplifier is needed. The sensor measurements required 5 ps duration
pulses that were only 5 W. That is less than 1 W averaged over the entire measure-
ment. This power requirement is well within the capabilities of a portable battery-
operated device. If the sensor is implanted very close to the skin's surface, the mag-
nets can also be miniaturized and it would be possible to build a wearable reader
that the patient could use at home. Patients can be released sooner from the hospital
because the system will monitor the patient at home. It can detect early warning
signs and inform the patient to visit the doctor before it is too late.
Commercialization
Commercializing the sensor will involve carefully selecting an unmet clinical need
with a short path to regulatory approval. The ideal application is one that would
benefit from an implanted sensor, will require only a very short implantation period,
and will have a clearly defined end point. One example is a subcutaneous cardiac
toxicity sensor for chemotherapy patients. Cardiac toxicity is of great concern when
choosing chemotherapeutic dose and is often a cause to reduce the dose or to suspend
treatment altogether. The sensor would be implanted only for the duration of therapy
and could easily be removed if any complications were to arise. The goal would be
for the sensor to predict cardiotoxicity earlier on so that the dose can be adjusted
sooner. The first trial would involve acquiring the sensor data while the patients
receive the standard of care. The sensors would be explanted at the end of the
study. The sensor's predictive value can be assessed by how well the sensor readings
correlated to outcomes or actions later on. For example, an elevated reading on day
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two may correlate with the reduction of dose on day ten. A follow-up trial would
then compare the standard of care to a sensor-assisted treatment plan in which the
sensor's predictions are used to adjust the dose.
A second short-term application would be a sensor to monitor tumors that will be
treated with radiotherapy before being surgically resected. Some tumors cannot be
removed surgically because of their size and location. Patients must first receive
radiation therapy for several weeks to reduce the tumor size before surgery [106].
An oxygen sensor, implanted before the radiation therapy, will measure the tumor
oxygenation over the course of treatment. The sensor will be removed when the
tumor is resected. No change to the standard of care would be made except for the
sensor implantion, which would involve little to no additional risk to the patient.
The data collected from the sensor will be compared to the patient's progress to
determine whether the sensor could predict the therapeutic outcome. The ability to
predict early on whether the radiation therapy is working or whether a higher dose
is needed would be particularly beneficial to the patient.
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Appendix A
Least-squares echo estimation
This chapter presents an improvement to the standard acquisition method in single-
sided NMR systems to increase the signal-to-noise ratio. It uses a least squares
estimate of the entire echo rather than just the peak.
Single-sided NMR systems are compact and portable and allow for measurement on
samples that will not fit inside the bore of a superconducting magnet in an NMR
spectrometer or an MRI [107]. These systems use an array of permanent magnets to
create a uniform field in a remote region [108] or a fixed gradient that allows slice-
selective measurements and profiling [109, 44]. Non-destructive testing is essential
for historical artifacts [110, 111] but is also useful for quality control on a production
line [112]. These advantages come at the cost of lowered signal-to-noise ratio. The
sensitive region is far from the magnet, and the magnetic fields tend to be very weak.
The oscillating field is also weak, and proper shielding becomes difficult.
Relaxation time measurements almost exclusively rely on spin-echo sequences. The
echoes are typically short lived owing to the spread in Larmor frequency across
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the sample, and the width of the echo is ultimately determined by the bandwidth
of the excitation pulse. Setting up for measurement requires identifying the echo
and adjusting the receiver phase such that the 'real' and 'imaginary' channels of the
quadrature-detected signal correspond to the even and odd decomposition of the echo
envelope. The peak resides on the real channel, while the imaginary channel is zero.
The acquisition window is centered and narrowed to capture the peak amplitude
from real channel. Relaxation times are measured by tracking the decay of the echo
amplitude across many echoes.
Acquiring only the peak avoids collecting noise when no signal is expected. An op-
timum acquisition time window exists that maximizes the signal-to-noise ratio. The
window is widened until the accumulated signal drops below a noise threshold [113].
The optimum window is determined by the echo shape and the noise level. It must
be found empirically.
A.1 Theory
The proposed method uses a standard CPMG pulse sequence with an expanded
acquisition window to capture and record every echo envelope. The detection scheme
requires a known ideal echo, F(t), such that the acquired data for each echo would
be given by
D(t) = aF(t) + e(t) (A.1)
where a is the echo amplitude and e is the noise in the measurement. The NMR
receiver will record N, complex samples from each of Ne echoes and store the data
in a matrix, D, of size N, x Ne. The echo function should also be in sampled form,
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F, of size N, x 1.
It is assumed that the echo duration is much shorter than the relaxation time so that
relaxation during the echo is negligible. If D were real then it can be represented as:
D =F-A+E (A.2)
where A is a vector of echo amplitudes and E is the noise. Calculating the echo am-
plitudes is achieved by finding the value of A that minimizes the error, ID- = F -A 2.
This formulation is precisely the least squares problem with a single parameter [114].
The solution is
FTD
A = F (A.3)
FT F
The equation is simplified by normalizing the echo function, such that vFTF = 1.
The acquired echo data are not real but, rather, are complex numbers with two
orthogonal components. The echo amplitude, a, scales both the real and imaginary
signals, and, therefore, Equation (A.2) can be written in complex form:
DR+ iD 1 = (FR + iFj) - A + (ER+ iEj) (A.4)
where i = v/ -. The real and imaginary components represent two sets of equations
and can be stacked vertically.
DR FR A + ER (A.5)
This has the same form as Equation (A.2), and the solution of Equation (A.3) uses
all of the data from both channels.
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The only outstanding issue is how the ideal echo function is found. The shape will
differ depending on the system parameters, the acquisition settings, and the pulse
sequence. A spin-echo sequence can yield thousands of echoes all with the same
echo shape. The function, F, can be generated by summing the echoes in the data.
Implicit in this approach is the assumption that the ideal echo function represents
a positive echo, a > 0. If the pulse sequence generates a negative amplitude, such
as inversion recovery, then F should be multiplied by minus one. Unlike magnitude
detection, the least-squares method can measure negative data, and it also automat-
ically corrects for the echo position and the receiver phase angle.
A.2 Experiment
The least squares echo approximation was demonstrated by measuring the transverse
relaxation time (T2) of a dilute solution of copper sulfate on a single-sided NMR sys-
tem (NMR-MOUSE/KEA, Magritek, Wellington, New Zealand). A standard CPMG
pulse sequence was used to measure the transverse relaxation time (1000 echoes, TE
80 ps, 32 scans). The acquisition window was expanded to store the entire echo. Each
echo consisted of 32 complex points stored as a single vector of 64 real values. The
receiver phase and acquisition window were adjusted to maximize the real channel
and to center the echo for comparison with the integral method. The sample was
measured 1,145 times.
Figure A-1 shows the full data acquisition and highlights the peak point that is
typically acquired and stored. The black line shows the outline of the echo estimate
fit to the data by least-squares. The effect of changing the acquisition window is
achieved by taking a subset of the data from the full data set. Echo amplitudes
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Figure A-i: Typical signal acquired from one echo. The echo envelope is formed by
summing multiple echoes at the start of a multi-echo sequence.
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were calculated either by the least-squares method or by integrating the data in the
subset. The echo peaks were fit to a function:
A(t) = aoe-t/T2 (A.6)
The error is calculated by the root mean square error between the fit and the data
and is used to calculate the signal-to-noise ratio. Figure A-2 shows the effect of
the acquisition window on the signal-to-noise ratio. The integral method follows
the trend described in the literature [113]: a wider acquisition window increases the
signal-to-noise ratio only if the signal is above a noise threshold otherwise the noise
begins to dominate. The least-squares approach gives more weight to those data
points where the signal is expected. The echo function has zero entries where no
signal is expected, and therefore no noise from signal-free acquisition enteres the
data. Acquiring more data is always preferable, and the data from the imaginary
channel increase the signal-to-noise ratio by an additional 5%.
The receiver phase angle was changed in a second experiment to explore how the
receiver angle affects the measured T2. The same sample was measured at phase
angles from -120' to 1200 in 30 'steps.
The measured echo envelopes are shown in Figure A-3 as a function of the receiver
angle. The dashed lines trace the peak of the real and imaginary components. All
of the data were used in the least squares estimate, and the acquisition window was
optimized for the integral method. The data were fit to Equation (A.6) as usual,
allowing for negative amplitudes.
The least squares method relies on the assumption that the echo envelope retains
its shape throughout the relaxation process and that only the amplitude changes.
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Figure A-2: The signal-to-noise ratio of the least squares estimate increases as more
data is acquired. Increasing the integration time eventually adds noise but no data
and leads to a reduction in SNR.
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Figure A-5: The echo envelope changes over the first few echoes.
The first five echoes are shown in Figure A-5. The first echo is typically of a lower
amplitude than the second and is often ignored in data analysis. The side lobes of
the main echo appear to have a shape change, but the amplitude is dominated by the
larger peak. Echoes 5 through 100 are normalized in area and overlaid in Figure A-6.
The echoes have a similar enough shape that any deviations are well within the noise
of each measurement.
The least squares estimate offers an optimal echo acquisition method with very little
computational effort and with no prior knowledge of the shape of the echo. The
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Figure A-6: Normalized signal amplitude for echoes 5 to 100. The echo shape is
constant within the noise of any one measurement.
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key advantage over the integration of the central portion of the peak is that a wider
window never decreases the SNR. This is especially important for inhomogeneous
field NMR because the width of the echo depends on the excitation pulse. The
optimum integration width must be found for each set of parameters. Least-squared
error method does not require any optimization since the echo estimate eliminates any
data where no signal is expected. Any pulse sequence can be modified by increasing
the acquisition window to the maximum allowed and storing all the data at the
maximum sampling rate.
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Appendix B
Numerical computation of mutual
inductance
Two coils or loops of wire have a mutual inductance between them given by
M PO d1- d12  (B.1)
47r r r2C2 C1 I2I
A general case analytical solution does not exist for arbitrary shapes and quickly
becomes intractable for all but the simplest of cases. A numerical method that can
handle any shape in any orientation is much preferred.
Equation (B.1) must be converted into a summation rather than an integral. Each
coil is defined as a sequence of n segments bounded by n + 1 points in Cartesian
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space:
X 1  Y1 Z1
X 2  Y2 Z2
C= X 3  Y3 Z3  , (B.2)
Xn+1 Yn+1 Zn+1
where each row is considered a bounding point of a line segment. Equivalently,
each segment can be defined by a midpoint and a vector direction. This description
simplifies the subsequent calculations since the vector potential will be in the same
direction as each segment. The midpoints of each segment will be used to calculate
the distances between vectors and are defined as
X 1 X 2  Y1 +Y2 Z1 Z2
X2 +X 3  Y2 +Y3 Z2 + Z 3
-. 1
R =3 + X 4  Y3 + Y4 Z3 + Z4 (B.3)2
Xn +Xn+1 Yn +Yn+1 Zn + ZrL1
The segment directions are equivalent to current vectors if I = 1 A and are calculated
by
X 2 -X 1  Y2-Y1 Z2 -Z 1
X 3 -X 2  Y3-2 Z2 -Z 2
L=I X4 
- 
X 3  Y4 - Y3 Z3 - Z 3  (B.4)
-n+1 ~ n in+1 Yn Zn+ 1 - Zn
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The line vectors would need to be scaled by I in order to calculate a true vector
potential, but for calculating mutual inductance unit current is preferred. Coil C1
has n segments and coil C2 has m segments. The vector potential is calculated at
each point of R 2 and has m x 3 elements:
(B.5)POI n 11iAr2,j)= 47r 
_ ri, - r2,j
Summing the dot product of each element of A with its corresponding line segment
in L 2 gives the mutual inductance:
m
M = ZI1( 2 ,j)j=1
(B.6)
This formulation is extremely powerful when considering coils at arbitrary orienta-
tions to each other. The coils are defined centered at the origin with an axis along x.
One coil is then rotated and translated to the desired position. The rotation matrix
is
[1
S= 0
0
0
cos(o)
- sin(O)
0 cos(0)
sin(O) 0
cos(o) sin(6)
0
1
0
- sin(0)
0
cos(O)
cos()
- sin(#)
0
sin(#)
cos(#)
0
0
0
1
(B.7)
The rotated direction vectors are Lot =
lated to the coil's new center coordinates
origin. The new midpoints are Rrot,trans
extremely fast even on a modest PC with
for thousand-segment coils.
LQ. The midpoints must also be trans-
(X, Y, Z) since they are referenced to the
= RQ + (X, Y, Z). The computation is
calculation of M taking a few milliseconds
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